<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id>
      <journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id>
      <journal-id journal-id-type="publisher-id">vaccines</journal-id>
      <journal-title-group>
        <journal-title>Vaccines</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2076-393X</issn>
      <publisher>
        <publisher-name>MDPI</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">36851141</article-id>
      <article-id pub-id-type="pmc">9966016</article-id>
      <article-id pub-id-type="doi">10.3390/vaccines11020263</article-id>
      <article-id pub-id-type="publisher-id">vaccines-11-00263</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Proteome-Wide Screening of Potential Vaccine Targets against <italic toggle="yes">Brucella melitensis</italic></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Malik</surname>
            <given-names>Mahnoor</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
          <xref rid="af1-vaccines-11-00263" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Khan</surname>
            <given-names>Saifullah</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
          <xref rid="af2-vaccines-11-00263" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ullah</surname>
            <given-names>Asad</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
          <xref rid="af1-vaccines-11-00263" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hassan</surname>
            <given-names>Muhammad</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
          <xref rid="af3-vaccines-11-00263" ref-type="aff">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Haq</surname>
            <given-names>Mahboob ul</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
          <xref rid="af4-vaccines-11-00263" ref-type="aff">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0754-1742</contrib-id>
          <name>
            <surname>Ahmad</surname>
            <given-names>Sajjad</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
          <xref rid="af1-vaccines-11-00263" ref-type="aff">1</xref>
          <xref rid="c1-vaccines-11-00263" ref-type="corresp">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0889-2886</contrib-id>
          <name>
            <surname>Al-Harbi</surname>
            <given-names>Alhanouf I.</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
          <xref rid="af5-vaccines-11-00263" ref-type="aff">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sanami</surname>
            <given-names>Samira</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
          <xref rid="af6-vaccines-11-00263" ref-type="aff">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Abideen</surname>
            <given-names>Syed Ainul</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
          <xref rid="af7-vaccines-11-00263" ref-type="aff">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Irfan</surname>
            <given-names>Muhammad</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
          <xref rid="af8-vaccines-11-00263" ref-type="aff">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8375-8532</contrib-id>
          <name>
            <surname>Khurram</surname>
            <given-names>Muhammad</given-names>
          </name>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
          <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
          <xref rid="af4-vaccines-11-00263" ref-type="aff">4</xref>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>McConnell</surname>
            <given-names>Michael J.</given-names>
          </name>
          <role>Academic Editor</role>
        </contrib>
        <contrib contrib-type="editor">
          <name>
            <surname>Siles</surname>
            <given-names>Mireia L&#xF3;pez</given-names>
          </name>
          <role>Academic Editor</role>
        </contrib>
        <contrib contrib-type="editor">
          <name>
            <surname>Lugo</surname>
            <given-names>Andr&#xE9;s Corral</given-names>
          </name>
          <role>Academic Editor</role>
        </contrib>
      </contrib-group>
      <aff id="af1-vaccines-11-00263"><label>1</label>Department of Health and Biological Sciences, Abasyn University, Peshawar 25000, Pakistan</aff>
      <aff id="af2-vaccines-11-00263"><label>2</label>Institute of Biotechnology and Microbiology, Bacha Khan University, Charsadda 24550, Pakistan</aff>
      <aff id="af3-vaccines-11-00263"><label>3</label>Department of Pharmacy, Bacha Khan University, Charsadda 24461, Pakistan</aff>
      <aff id="af4-vaccines-11-00263"><label>4</label>Department of Pharmacy, Abasyn University, Peshawar 25000, Pakistan</aff>
      <aff id="af5-vaccines-11-00263"><label>5</label>Department of Medical Laboratory, College of Applied Medical Sciences, Taibah University, Yanbu 42353, Saudi Arabia</aff>
      <aff id="af6-vaccines-11-00263"><label>6</label>Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord 8815713471, Iran</aff>
      <aff id="af7-vaccines-11-00263"><label>7</label>School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China</aff>
      <aff id="af8-vaccines-11-00263"><label>8</label>Department of Oral Biology, College of Dentistry, University of Florida, Gainesville, FL 32611, USA</aff>
      <author-notes>
        <corresp id="c1-vaccines-11-00263"><label>*</label>Correspondence: <email>sajjad.ahmad@abasyn.edu.pk</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>25</day>
        <month>1</month>
        <year>2023</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>2</month>
        <year>2023</year>
      </pub-date>
      <volume>11</volume>
      <issue>2</issue>
      <elocation-id>263</elocation-id>
      <history>
        <date date-type="received">
          <day>23</day>
          <month>11</month>
          <year>2022</year>
        </date>
        <date date-type="rev-recd">
          <day>16</day>
          <month>1</month>
          <year>2023</year>
        </date>
        <date date-type="accepted">
          <day>23</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2023 by the authors.</copyright-statement>
        <copyright-year>2023</copyright-year>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
          <license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <p>The ongoing antibiotic-resistance crisis is becoming a global problem affecting public health. Urgent efforts are required to design novel therapeutics against pathogenic bacterial species. <italic toggle="yes">Brucella melitensis</italic> is an etiological agent of brucellosis, which mostly affects sheep and goats but several cases have also been reported in cattle, water buffalo, yaks and dogs. Infected animals also represent the major source of infection for humans. Development of safer and effective vaccines for brucellosis remains a priority to support disease control and eradication in animals and to prevent infection to humans. In this research study, we designed an in-silico multi-epitopes vaccine for <italic toggle="yes">B. melitensis</italic> using computational approaches. The pathogen core proteome was screened for good vaccine candidates using subtractive proteomics, reverse vaccinology and immunoinformatic tools. In total, 10 proteins: catalase; siderophore ABC transporter substrate-binding protein; pyridoxamine 5&#x2032;-phosphate oxidase; superoxide dismutase; peptidylprolyl isomerase; superoxide dismutase family protein; septation protein A; hypothetical protein; binding-protein-dependent transport systems inner membrane component; and 4-hydroxy-2-oxoheptanedioate aldolase were selected for epitopes prediction. To induce cellular and antibody base immune responses, the vaccine must comprise both B and T-cells epitopes. The epitopes were next screened for antigenicity, allergic nature and water solubility and the probable antigenic, non-allergic, water-soluble and non-toxic nine epitopes were shortlisted for multi-epitopes vaccine construction. The designed vaccine construct comprises 274 amino acid long sequences having a molecular weight of 28.14 kDa and instability index of 27.62. The vaccine construct was further assessed for binding efficacy with immune cell receptors. Docking results revealed that the designed vaccine had good binding potency with selected immune cell receptors. Furthermore, vaccine-MHC-I, vaccine-MHC-II and vaccine-TLR-4 complexes were opted based on a least-binding energy score of &#x2212;5.48 kcal/mol, 0.64 kcal/mol and &#x2212;2.69 kcal/mol. Those selected were then energy refined and subjected to simulation studies to understand dynamic movements of the docked complexes. The docking results were further validated through MMPBSA and MMGBSA analyses. The MMPBSA calculated &#x2212;235.18 kcal/mol, &#x2212;206.79 kcal/mol, and &#x2212;215.73 kcal/mol net binding free energy, while MMGBSA estimated &#x2212;259.48 kcal/mol, &#x2212;206.79 kcal/mol and &#x2212;215.73 kcal/mol for TLR-4, MHC-I and MHC-II complexes, respectively. These findings were validated by water-swap and entropy calculations. Overall, the designed vaccine construct can evoke proper immune responses and the construct could be helpful for experimental researchers in formulation of a protective vaccine against the targeted pathogen for both animal and human use.</p>
      </abstract>
      <kwd-group>
        <kwd>
          <italic toggle="yes">Brucella melitensis</italic>
        </kwd>
        <kwd>reverse vaccinology</kwd>
        <kwd>vaccine</kwd>
        <kwd>molecular modelling</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>Department of Health and Biological Sciences, Abasyn University</funding-source>
        </award-group>
        <funding-statement>The authors are thankful to the Department of Health and Biological Sciences, Abasyn University, Peshawar, Pakistan for financial support.</funding-statement>
      </funding-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="sec1-vaccines-11-00263">
      <title>1. Introduction</title>
      <p>Antibiotic resistance by bacteria significantly contributes to human morbidity and mortality. This is due to the irrational use of antibiotics in humans, animals, the environment and agricultural fields [<xref rid="B1-vaccines-11-00263" ref-type="bibr">1</xref>]. Antibiotic resistance is a bacterial evolution process to adjust to changing environmental milieu [<xref rid="B2-vaccines-11-00263" ref-type="bibr">2</xref>]. Novel approaches are needed to combat this alarming global health concern [<xref rid="B3-vaccines-11-00263" ref-type="bibr">3</xref>]. The use of bacterial genomic information in vaccine design is a promising approach at the present time. This technique is referred to as reverse vaccinology, which has remarkably changed the field of vaccine design [<xref rid="B4-vaccines-11-00263" ref-type="bibr">4</xref>]. Vaccines can be used to provoke host immune responses against infectious pathogens. Antigens can be either biological or synthetic in nature [<xref rid="B5-vaccines-11-00263" ref-type="bibr">5</xref>].</p>
      <p>In the beginning of 15th century, smallpox disease resulted in high mortality and morbidity rates. Both Turks and Chinese were trying to induce immunity against smallpox by using powder smallpox lesions [<xref rid="B6-vaccines-11-00263" ref-type="bibr">6</xref>]. Pasteur&#x2019;s vaccinology concept was used by Salk and Sabin to design an effective poliovirus vaccine. Reverse vaccinology is a novel tool for vaccine production, which compared to traditional vaccines is a cheap process and can be done in a short time [<xref rid="B7-vaccines-11-00263" ref-type="bibr">7</xref>]. Identification of new vaccine targets through genomics and computational techniques has not only speed up the vaccine development process but also delivers new antigens not disclosed through experimental methods [<xref rid="B8-vaccines-11-00263" ref-type="bibr">8</xref>]. For finding putative surface-associated proteins, reverse vaccinology is used without any culturing of microorganisms [<xref rid="B9-vaccines-11-00263" ref-type="bibr">9</xref>]. Using the same process, meningococcal serogroup B (4DMenB) vaccine was developed [<xref rid="B10-vaccines-11-00263" ref-type="bibr">10</xref>]. Compared to simple reverse vaccinology, pan-genomic reverse vaccinology is generally more effective as it screens highly conserved targets [<xref rid="B11-vaccines-11-00263" ref-type="bibr">11</xref>]. As an example, for <italic toggle="yes">Streptococcus agalactiae</italic> four different protective antigens were unveiled by pan-genomic reverse vaccinology [<xref rid="B12-vaccines-11-00263" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-11-00263" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-11-00263" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-11-00263" ref-type="bibr">15</xref>].</p>
      <p>In this study, comparative genomics and reverse vaccinology methods were used for identification of protective vaccine antigens against <italic toggle="yes">Brucella melitensis</italic>, which is a Gram-negative coccobacillus bacterium from the <italic toggle="yes">Brucellaceae</italic> family [<xref rid="B16-vaccines-11-00263" ref-type="bibr">16</xref>]. <italic toggle="yes">B. melitensis</italic> is an etiological agent of brucellosis, which mostly affects sheep and goats but several cases have also been reported in cattle, water buffalo, yaks and dogs [<xref rid="B17-vaccines-11-00263" ref-type="bibr">17</xref>]. The pathogen causes brucellosis in goats and Malta fever in humans [<xref rid="B17-vaccines-11-00263" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-11-00263" ref-type="bibr">18</xref>]. Infected animals represent the major source of infection for humans, through direct exposure or through consumption of contaminated and unpasteurized dairy products. In endemic areas, vaccination of susceptible animals would reduce disease prevalence also limiting the risk of disease transmission to humans [<xref rid="B19-vaccines-11-00263" ref-type="bibr">19</xref>]. Previous efforts on <italic toggle="yes">B. melitensis</italic> vaccination are dominated by work on the Rev1 vaccine which is effective against sheep and goat brucellosis [<xref rid="B20-vaccines-11-00263" ref-type="bibr">20</xref>]. The vaccine comprises smooth lipopolysaccharide with O-polysaccharide able to elicit strong antibody responses [<xref rid="B21-vaccines-11-00263" ref-type="bibr">21</xref>]. Rev1 is a live attenuated vaccine and despite its efficacy, several drawbacks remain due to its residual pathogenicity. The Rev1 vaccine may also result in abortion in pregnant animals [<xref rid="B22-vaccines-11-00263" ref-type="bibr">22</xref>,<xref rid="B23-vaccines-11-00263" ref-type="bibr">23</xref>]. Previous attempts to produce safer and effective recombinant brucella vaccines included two antigens (periplasmic bp26 and chaperone trigger factor proteins); however, both candidates were not able to induce protective and accurate immune responses [<xref rid="B22-vaccines-11-00263" ref-type="bibr">22</xref>,<xref rid="B24-vaccines-11-00263" ref-type="bibr">24</xref>]. Despite these efforts, no licensed vaccine is available to prevent brucellosis infection. In addition, drug-resistant strains of <italic toggle="yes">B. melitensis</italic> are making the situation worse. Thus, considering this, herein we applied an integrated approach comprising comparative genomics, subtractive proteomics, reverse vaccinology, immunoinformatic, and biophysics techniques to identify protective antigens from <italic toggle="yes">B. melitensis</italic> completely sequenced genomes and designed a multi-epitopes vaccine [<xref rid="B25-vaccines-11-00263" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-11-00263" ref-type="bibr">26</xref>,<xref rid="B27-vaccines-11-00263" ref-type="bibr">27</xref>,<xref rid="B28-vaccines-11-00263" ref-type="bibr">28</xref>,<xref rid="B29-vaccines-11-00263" ref-type="bibr">29</xref>,<xref rid="B30-vaccines-11-00263" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-11-00263" ref-type="bibr">31</xref>,<xref rid="B32-vaccines-11-00263" ref-type="bibr">32</xref>,<xref rid="B33-vaccines-11-00263" ref-type="bibr">33</xref>]. The designed vaccine construct then was examined for interactions with host immune receptors to check whether the vaccine is able to be presented to the host immunity system. The findings of this study may help in formulating vaccines design against <italic toggle="yes">B. melitensis</italic>.</p>
    </sec>
    <sec id="sec2-vaccines-11-00263">
      <title>2. Materials and Methods</title>
      <p>The study framework used for designing a multi-epitopes vaccine against <italic toggle="yes">B. melitensis</italic> is illustrated in <xref rid="vaccines-11-00263-f001" ref-type="fig">Figure 1</xref>.</p>
      <sec id="sec2dot1-vaccines-11-00263">
        <title>2.1. Proteomes Retrieval of B. melitensis</title>
        <p>The complete proteomic data of fully sequenced <italic toggle="yes">B. melitensis</italic> strains were extracted from the national center for biotechnological information (NCBI) genome database [<xref rid="B34-vaccines-11-00263" ref-type="bibr">34</xref>]. The proteomic data were retrieved in FASTA format.</p>
      </sec>
      <sec id="sec2dot2-vaccines-11-00263">
        <title>2.2. BPGA Analysis</title>
        <p>For identification of suitable vaccine candidates, all the proteomes were screened with the bacterial pan genomic analysis (BPGA) tool [<xref rid="B35-vaccines-11-00263" ref-type="bibr">35</xref>]. During this analysis, different sets of proteins were identified such as core, accessory and unique. The core proteins were picked and used in downward analysis as they have broad spectrum applicability [<xref rid="B36-vaccines-11-00263" ref-type="bibr">36</xref>,<xref rid="B37-vaccines-11-00263" ref-type="bibr">37</xref>,<xref rid="B38-vaccines-11-00263" ref-type="bibr">38</xref>,<xref rid="B39-vaccines-11-00263" ref-type="bibr">39</xref>].</p>
      </sec>
      <sec id="sec2dot3-vaccines-11-00263">
        <title>2.3. CD-Hit Analysis</title>
        <p>In the pre-screening phase, the core sequences were subjected to redundancy checks to remove duplicate copies of the proteins [<xref rid="B40-vaccines-11-00263" ref-type="bibr">40</xref>]. The non-redundant proteins are single presentations in the proteome and do not require extra computational cost. In the CD-hit (cluster data with high identity with tolerance) analysis, core proteins were analyzed for the presence of redundant proteins [<xref rid="B41-vaccines-11-00263" ref-type="bibr">41</xref>,<xref rid="B42-vaccines-11-00263" ref-type="bibr">42</xref>,<xref rid="B43-vaccines-11-00263" ref-type="bibr">43</xref>]. Non-redundant proteins were selected as the best candidates for the vaccine design [<xref rid="B44-vaccines-11-00263" ref-type="bibr">44</xref>,<xref rid="B45-vaccines-11-00263" ref-type="bibr">45</xref>]. The core proteins were clustered at a threshold of 0.5 which means that the sequences that were 50% similar were clustered together.</p>
      </sec>
      <sec id="sec2dot4-vaccines-11-00263">
        <title>2.4. Subcellular Localization Phase</title>
        <p>In the field of vaccine design, surface proteins elicit robust immune response [<xref rid="B46-vaccines-11-00263" ref-type="bibr">46</xref>,<xref rid="B47-vaccines-11-00263" ref-type="bibr">47</xref>,<xref rid="B48-vaccines-11-00263" ref-type="bibr">48</xref>]. The non-redundant proteome was examined though PSORTb 3.0, which is a bacterial protein subcellular localization prediction program [<xref rid="B49-vaccines-11-00263" ref-type="bibr">49</xref>].</p>
      </sec>
      <sec id="sec2dot5-vaccines-11-00263">
        <title>2.5. Homology Check</title>
        <p>In the homology check, the shortlisted proteins were blast through the BLASTp (basic local alignment search tool) against the human proteomes for sequence similarity [<xref rid="B50-vaccines-11-00263" ref-type="bibr">50</xref>]. Those proteins with E values &lt; 1.0<sup>&#x2212;4</sup>, bit scores &lt;100 and &lt;30% sequence identity were selected [<xref rid="B36-vaccines-11-00263" ref-type="bibr">36</xref>,<xref rid="B37-vaccines-11-00263" ref-type="bibr">37</xref>]. Homologous proteins provoke autoimmune reactions [<xref rid="B51-vaccines-11-00263" ref-type="bibr">51</xref>]. A similar homology check was also performed against intestinal probiotic bacteria <italic toggle="yes">Lactobacillus rhamnosus</italic> (taxid: 47715), <italic toggle="yes">L. casei</italic> (taxid: 1582) and <italic toggle="yes">L. johnsonii</italic> (taxid: 33959) to avoid their function inhibition [<xref rid="B52-vaccines-11-00263" ref-type="bibr">52</xref>].</p>
      </sec>
      <sec id="sec2dot6-vaccines-11-00263">
        <title>2.6. Vaccine Candidate&#x2019;s Prioritization Phase</title>
        <p>In the vaccine candidate prioritization phase, the main focus was on prioritization of potential vaccine candidates for vaccine design.</p>
      </sec>
      <sec id="sec2dot7-vaccines-11-00263">
        <title>2.7. Virulent Protein Analysis</title>
        <p>Virulent proteins are good vaccine candidates as they have the ability to stimulate immune responses of the host [<xref rid="B53-vaccines-11-00263" ref-type="bibr">53</xref>]. The proteins were blast using BLASTp against the core virulent factor database (VFDB) [<xref rid="B54-vaccines-11-00263" ref-type="bibr">54</xref>]. The proteins selected as the best choices for vaccine design exhibited a sequence identity &#x2265;30% and a bit score &gt;100. Those proteins that were below the set parameters were discarded [<xref rid="B55-vaccines-11-00263" ref-type="bibr">55</xref>].</p>
      </sec>
      <sec id="sec2dot8-vaccines-11-00263">
        <title>2.8. Physiochemical Analysis</title>
        <p>The filtered proteins were analyzed for physiochemical properties including, molecular weight, atomic composition, instability index, theoretical PI, amino acid composition, aliphatic index, grand average of hydropath city (GRAVY) and estimated half-life [<xref rid="B56-vaccines-11-00263" ref-type="bibr">56</xref>]. These properties were analyzed using the ProtParam-2017 tool [<xref rid="B57-vaccines-11-00263" ref-type="bibr">57</xref>]. Those proteins having a molecular weight less than 110 kDa and thermostability index less than 40 were considered to be good candidates for vaccine design as they can be easily purified [<xref rid="B58-vaccines-11-00263" ref-type="bibr">58</xref>].</p>
      </sec>
      <sec id="sec2dot9-vaccines-11-00263">
        <title>2.9. Transmembrane Helices</title>
        <p>The proteins that have less transmembrane helicase were considered as good candidates for vaccine design [<xref rid="B31-vaccines-11-00263" ref-type="bibr">31</xref>,<xref rid="B33-vaccines-11-00263" ref-type="bibr">33</xref>]. For the analysis of transmembrane helicase, HMMTOP 2.0 [<xref rid="B59-vaccines-11-00263" ref-type="bibr">59</xref>] and TMHMM 2.0 [<xref rid="B60-vaccines-11-00263" ref-type="bibr">60</xref>] softwares were used. The threshold values were set at 0 and 1. Proteins that were exposed and had values of 0 and 1 were selected [<xref rid="B32-vaccines-11-00263" ref-type="bibr">32</xref>].</p>
      </sec>
      <sec id="sec2dot10-vaccines-11-00263">
        <title>2.10. Antigenicity Prediction</title>
        <p>For stimulation of the host immune system, foreign antigens should be capable of binding with the host immune cells; that capability of antigens is known as antigenicity [<xref rid="B61-vaccines-11-00263" ref-type="bibr">61</xref>]. For the detection of antigenicity of shortlisted proteins, the online server VaxiJen 2.0 was used [<xref rid="B62-vaccines-11-00263" ref-type="bibr">62</xref>]. The threshold value for the antigenicity of proteins was set at 0.4. Those proteins that had antigenicity scores &gt;0.5 were considered as good choices for vaccine design [<xref rid="B47-vaccines-11-00263" ref-type="bibr">47</xref>].</p>
      </sec>
      <sec id="sec2dot11-vaccines-11-00263">
        <title>2.11. Adhesion Probability Analysis</title>
        <p>For stimulation of the host immune system, vaccine antigens should be able to attach to the host cells and start the infection process to be recognized as antigens by the host immune system [<xref rid="B55-vaccines-11-00263" ref-type="bibr">55</xref>]. After attachment, adaptive immunity is developed which includes T cell receptors and antibodies [<xref rid="B63-vaccines-11-00263" ref-type="bibr">63</xref>]. For the analysis of the adhesion probability of proteins, the online server Vaxign was used [<xref rid="B64-vaccines-11-00263" ref-type="bibr">64</xref>]. The threshold for the selection of a good protein was set at &gt;0.5 [<xref rid="B36-vaccines-11-00263" ref-type="bibr">36</xref>].</p>
      </sec>
      <sec id="sec2dot12-vaccines-11-00263">
        <title>2.12. Allergenicity of the Proteins</title>
        <p>Those proteins that were allergens to the host were removed and only non-allergenic proteins were selected. The allergenicity of the proteins was determined through the online webserver AllerTOP 2.0 [<xref rid="B65-vaccines-11-00263" ref-type="bibr">65</xref>].</p>
      </sec>
      <sec id="sec2dot13-vaccines-11-00263">
        <title>2.13. Epitopes Prediction </title>
        <p>The epitope is the main part of the antigen to which the host immune cells bind. In prediction of epitopes, the B cell and T cell epitopes were analyzed via the immune epitope database (IEDB) tool [<xref rid="B66-vaccines-11-00263" ref-type="bibr">66</xref>]. The threshold for the IEDB server was set at 0.5. In the epitope-prediction phase, the B cell epitopes were first predicted and then T cell epitopes. The T cell epitopes were analyzed for the prediction of potential binding alleles for the major histocompatibility complex (MHC) class I and MHC class II. Prediction of binding of epitopes with the DRB*10101 alleles was analyzed using the MHcPred tool [<xref rid="B67-vaccines-11-00263" ref-type="bibr">67</xref>]. The threshold value set was IC50 values &#x2264;100 nM [<xref rid="B68-vaccines-11-00263" ref-type="bibr">68</xref>]. Those exceeding this threshold value were discarded.</p>
      </sec>
      <sec id="sec2dot14-vaccines-11-00263">
        <title>2.14. Physiochemical Analysis of the Predicated Epitopes</title>
        <p>The selected epitopes were then subjected to physiochemical properties analysis. The antigenicity and allergenicity of the epitopes were analyzed using VaxiJen 2.0 [<xref rid="B62-vaccines-11-00263" ref-type="bibr">62</xref>] and AllerTop 2.0 [<xref rid="B65-vaccines-11-00263" ref-type="bibr">65</xref>], respectively. The virulence property was checked via Virulentpred [<xref rid="B69-vaccines-11-00263" ref-type="bibr">69</xref>]. The antigenic and non-allergen epitopes were further analyzed using ToxinPred for toxicity [<xref rid="B70-vaccines-11-00263" ref-type="bibr">70</xref>]. All those epitopes having good water solubility were considered as good candidates. The ProteinSol tool (<uri xlink:href="https://protein-sol.manchester.ac.uk/">https://protein-sol.manchester.ac.uk/</uri>; accessed on 16 October 2022) was used for the prediction of water solubility.</p>
      </sec>
      <sec id="sec2dot15-vaccines-11-00263">
        <title>2.15. Multi-Epitopes Peptide Designing</title>
        <p>Peptide vaccines have weak ability to provoke host immune responses. The weak immunogenicity of the peptide vaccine can be handled with the technique of multi-epitopes peptide design [<xref rid="B71-vaccines-11-00263" ref-type="bibr">71</xref>,<xref rid="B72-vaccines-11-00263" ref-type="bibr">72</xref>]. In multi-epitopes peptide-design phase, immunodominant epitopes were linked to each other [<xref rid="B73-vaccines-11-00263" ref-type="bibr">73</xref>]. All the selected screened epitopes were linked with the Gly-Pro-Gly-Pro-Gly (GPGPG) linkers to build an immunopotent multi-epitopes peptide vaccine. Furthermore, the vaccine was linked with the highly immunopotent cholera toxin B adjuvant (CTB) for the enhancement of the vaccine immunogenicity [<xref rid="B74-vaccines-11-00263" ref-type="bibr">74</xref>,<xref rid="B75-vaccines-11-00263" ref-type="bibr">75</xref>]. The adjuvant binds to the monoganglioside GM1 receptor and is capable of stimulating cytokines, interferone, cellular and humoral immunity [<xref rid="B75-vaccines-11-00263" ref-type="bibr">75</xref>]. The adjuvant is used in vaccine design against cancer, tuberculosis and influenza [<xref rid="B76-vaccines-11-00263" ref-type="bibr">76</xref>].</p>
      </sec>
      <sec id="sec2dot16-vaccines-11-00263">
        <title>2.16. Physiochemical Properties Analysis</title>
        <p>The final vaccine construct was then subjected to various physiochemical properties. The online server ExPASy Protparam was used for the evaluation of molecular weight, number of amino acids, instability index, Grand average of hydropathicity (GRAVY), theoretical PI value and aliphatic index [<xref rid="B57-vaccines-11-00263" ref-type="bibr">57</xref>].</p>
      </sec>
      <sec id="sec2dot17-vaccines-11-00263">
        <title>2.17. Structural Prediction of Multi-Epitope Peptide</title>
        <p>The final vaccine construct was then run on the 3Dpro tool of the SCRATCH protein predictor for construction of the tertiary structure [<xref rid="B77-vaccines-11-00263" ref-type="bibr">77</xref>]. A good vaccine consists of a smaller number of loops, is small in size and simple in structure. For the removal of loops, the final vaccine construct was then run on the Galaxy Loop tool of the GalaxyWeb online server [<xref rid="B78-vaccines-11-00263" ref-type="bibr">78</xref>].</p>
      </sec>
      <sec id="sec2dot18-vaccines-11-00263">
        <title>2.18. Galaxy Refinement</title>
        <p>For the final refinement of the loop-modelled vaccine construct, the GalaxyRefine tool was used for the construction of side chains and removal of steric clashes [<xref rid="B79-vaccines-11-00263" ref-type="bibr">79</xref>]. The fully refined form of the vaccine construct was considered to be good candidate for vaccine design.</p>
      </sec>
      <sec id="sec2dot19-vaccines-11-00263">
        <title>2.19. Disulfide Engineering</title>
        <p>The stability of a vaccine is very important; thus, for better stability the bonding of the inner and outer chains was checked in silico. At the disulfide engineering phase, the Design 2.0 webserver was used for the introduction of disulfide bonds in the vaccine construct [<xref rid="B80-vaccines-11-00263" ref-type="bibr">80</xref>].</p>
      </sec>
      <sec id="sec2dot20-vaccines-11-00263">
        <title>2.20. In Silico Codon Optimization and Coding</title>
        <p>The sequence of the multi-epitope vaccine construct was translated into a DNA sequence and then cloned into the expression vector to be expressed in <italic toggle="yes">Escherichia coli</italic>. The conversion of the vaccine into DNA was performed via the Java Codon Adaptation Tool (JCat) [<xref rid="B81-vaccines-11-00263" ref-type="bibr">81</xref>]. The expression level of the cloned sequence was evaluated through the &#x201C;GC&#x2019; concentration and the &#x201C;Codon Adaptation Index score (CAI)&#x201D;. Preferably, the CAI score should be 1 and the GC content should be 30&#x2013;70% [<xref rid="B82-vaccines-11-00263" ref-type="bibr">82</xref>].</p>
      </sec>
      <sec id="sec2dot21-vaccines-11-00263">
        <title>2.21. Docking and Refinement</title>
        <p>The binding affinity of the multi-epitope vaccine construct with the immune cell receptors was analyzed through blind molecular docking [<xref rid="B83-vaccines-11-00263" ref-type="bibr">83</xref>]. In the PatchDock server [<xref rid="B84-vaccines-11-00263" ref-type="bibr">84</xref>], the TLR-4, MHC-I and MHC-&#x2161; receptors were selected. The tertiary structures of these receptors were collected from the Protein Data Bank (PDB) by using the codes 4G8A, 1I1Y and 1KG0, respectively. The output solutions were generated by the PatchDock server and were then subjected to further refinement via the online webserver fast interaction refinement in molecular docking (FireDock) [<xref rid="B85-vaccines-11-00263" ref-type="bibr">85</xref>]. After the refinements, those complexes that exhibited the least global energy were ranked at the top and were selected for further analysis. The intermolecular interactions of complexes were analyzed via UCSF Chimera software [<xref rid="B86-vaccines-11-00263" ref-type="bibr">86</xref>].</p>
      </sec>
      <sec id="sec2dot22-vaccines-11-00263">
        <title>2.22. Molecular Dynamics Stimulation (MDS) Assay </title>
        <p>The dynamic behavior of the vaccine complexes was analyzed by using a molecular dynamics stimulation approach. Based on the lowest global energy value, the complexes were chosen for the MDS [<xref rid="B87-vaccines-11-00263" ref-type="bibr">87</xref>]. The AMBER20 stimulation software was used for simulation on a timescale of 200 ns [<xref rid="B88-vaccines-11-00263" ref-type="bibr">88</xref>]. For the completion of system setup phase, preprocessing and final production phase, the AMBER SANDER module was used [<xref rid="B89-vaccines-11-00263" ref-type="bibr">89</xref>]. The intermolecular interactions in the MDS were defined by FF14SB force field [<xref rid="B90-vaccines-11-00263" ref-type="bibr">90</xref>]. SHAKE algorithm was used to constrain hydrogen bonds [<xref rid="B91-vaccines-11-00263" ref-type="bibr">91</xref>]. The pressure equilibrium of the system was maintained by NPT ensemble. For the evaluation of trajectories, the CPPTRAJ module was used [<xref rid="B92-vaccines-11-00263" ref-type="bibr">92</xref>]. To investigate structure stability of complexes, root mean square deviation (RMSD) and root mean square fluctuation (RMSF) plots were produced in XMGRCE [<xref rid="B93-vaccines-11-00263" ref-type="bibr">93</xref>].</p>
      </sec>
      <sec id="sec2dot23-vaccines-11-00263">
        <title>2.23. Free Energy of Immune Receptors and Vaccine Design</title>
        <p>The tool MMPBSA.py provided in AMBER20 was used for the determination of binding free energies of the docked complexes [<xref rid="B94-vaccines-11-00263" ref-type="bibr">94</xref>,<xref rid="B95-vaccines-11-00263" ref-type="bibr">95</xref>,<xref rid="B96-vaccines-11-00263" ref-type="bibr">96</xref>]. In binding free energy analysis, a total of 100 frames were selected from the trajectories. Vaccine immune receptor complexes are stable having lower free binding energies [<xref rid="B48-vaccines-11-00263" ref-type="bibr">48</xref>].</p>
      </sec>
      <sec id="sec2dot24-vaccines-11-00263">
        <title>2.24. WaterSwap Validation and Entropy Analysis</title>
        <p>The MMPBSA often ignore the water molecule contribution in bridging the vaccine and receptors residues. Therefore, water-swap analysis was conducted with default settings to reconfirm stable intermolecular interactions [<xref rid="B97-vaccines-11-00263" ref-type="bibr">97</xref>]. Also, entropy energy calculations were done on 5 frames using AMBER normal mode analysis [<xref rid="B98-vaccines-11-00263" ref-type="bibr">98</xref>].</p>
      </sec>
    </sec>
    <sec sec-type="results" id="sec3-vaccines-11-00263">
      <title>3. Results</title>
      <sec id="sec3dot1-vaccines-11-00263">
        <title>3.1. Retrieval of Complete Proteome, Bacterial Pan-Genome Analysis and Subtractive Proteomics Filters</title>
        <p>The study was commenced with the retrieval of 95 fully sequenced strains of <italic toggle="yes">B. melitensis</italic>. The extracted strains were subjected to bacterial pa-genome analysis steps for retrieval of core sequences. In total, 238,450 core sequences were predicted. The core proteins were good targets for broad spectrum vaccine development. The core sequences were further considered for redundancy analysis. The webserver revealed that the 238,450 core sequences consisted of 2551 non-redundant proteins and 235,899 redundant proteins. The redundant proteins were discarded, and the non-redundant proteins were further considered for surface-localization analysis. The non-redundant proteins are single presentations in the proteomes and require less computational expense to process them [<xref rid="B40-vaccines-11-00263" ref-type="bibr">40</xref>]. The analysis revealed that non-redundant proteins consisted of 26 outer-membrane, 9 extracellular and 71 periplasmic membrane proteins. Next, VFDB analysis was performed, which predicted that the surface localized proteins consisted of 12 virulent proteins. Virulent proteins are good vaccine targets as they have antigenic epitopes capable of stimulating immune responses [<xref rid="B46-vaccines-11-00263" ref-type="bibr">46</xref>]. In 12 virulent proteins, 3 proteins were predicted to have more than 1 transmembrane helix. Overall, 12 proteins were predicted to be probably antigenic, have good water solubility and be non-toxic. Moreover, no physiochemically unstable, host or normal flora similar proteins were found. The category and number of proteins are presented in <xref rid="vaccines-11-00263-f002" ref-type="fig">Figure 2</xref>. The size of each proteome is presented in <xref rid="vaccines-11-00263-f003" ref-type="fig">Figure 3</xref>.</p>
      </sec>
      <sec id="sec3dot2-vaccines-11-00263">
        <title>3.2. Epitopes Prediction </title>
        <p>B and B-cell derived T-cell epitopes were predicted from the shortlisted 11 proteins given in <xref rid="vaccines-11-00263-t001" ref-type="table">Table 1</xref>. The predicted B-cell epitopes were further utilized for T-cell epitopes. The predicted MHC-I and MHC-II epitopes are tabulated in <xref rid="app1-vaccines-11-00263" ref-type="app">Table S1</xref> with least percentile scores. The common and lowest percentile score epitopes were opted for downward analyses.</p>
      </sec>
      <sec id="sec3dot3-vaccines-11-00263">
        <title>3.3. Selection of Epitopes for Multi-Epitopes Vaccine Construction</title>
        <p>Final set epitopes were selected for vaccine construct by applying several filters. Only antigenic, allergenic, water solubility and non-toxic B and B-cell derived T-cell epitopes were considered. <xref rid="vaccines-11-00263-t002" ref-type="table">Table 2</xref> shows selected epitopes utilized in multi-epitopes vaccine construction. The schematic diagram of vaccine construct comprising selected epitopes is presented in <xref rid="vaccines-11-00263-f004" ref-type="fig">Figure 4</xref>.</p>
      </sec>
      <sec id="sec3dot4-vaccines-11-00263">
        <title>3.4. Structure Prediction and Disulfide Engineering</title>
        <p>The vaccine 3D structure was predicted using a scratch predictor. The structure of the vaccine comprises cholera toxin B subunit as an adjuvant molecule, EAAAK and GPGPG linkers along with selected epitopes as presented in <xref rid="vaccines-11-00263-f005" ref-type="fig">Figure 5</xref>. The EAAAK and GPGPG linkers are rigid in nature and keep the epitopes separated which will allow the epitopes to be recognized by the host immune system for efficient recognition and processing [<xref rid="B38-vaccines-11-00263" ref-type="bibr">38</xref>]. The adjuvant cholera toxin B subunit is considered a powerful adjuvant as it generates specific immunity and mucosal antibody responses. The adjuvant binds to GM1 ganglioside, which is present on antigen-presenting cells, lymphocytes and epithelia cells. The adjuvant conjugation to antigens can result in activation of dendritic cells, decrease in antigen dose, and enhanced B and T-cell responses [<xref rid="B75-vaccines-11-00263" ref-type="bibr">75</xref>,<xref rid="B76-vaccines-11-00263" ref-type="bibr">76</xref>,<xref rid="B99-vaccines-11-00263" ref-type="bibr">99</xref>]. Furthermore, to retain structural stability of the vaccine, disulfide bonds were established between weak energy pairs. The enzymatic sensitive residue bonds were supplemented by cysteine bonds. The pairs of amino-acid residues that were disulfide engineered are tabulated in <xref rid="vaccines-11-00263-t003" ref-type="table">Table 3</xref> and presented in <xref rid="vaccines-11-00263-f006" ref-type="fig">Figure 6</xref> by yellow sticks.</p>
      </sec>
      <sec id="sec3dot5-vaccines-11-00263">
        <title>3.5. Loops Refinement</title>
        <p>In the loop-refinement phase, the structure of the designed vaccine construct was examined for loops refinement. A total of 10 refine models were generated and model 1 was selected for docking analysis. The top 10 refined models are tabulated in <xref rid="vaccines-11-00263-t004" ref-type="table">Table 4</xref>. The refined model has a good MolProbity score of 1.475, improved clash score of 2.3 and high percentage of residues in Rama-favored regions (92.6).</p>
      </sec>
      <sec id="sec3dot6-vaccines-11-00263">
        <title>3.6. Codon Optimization Phase</title>
        <p>The sequence of the multi-epitopes vaccine construct was translated into a DNA sequence and then cloned into the expression system of <italic toggle="yes">Escherichia coli</italic>. This was carried out to get higher expression of the cloned vaccine as E. coli is a good expression system. The CAI score of the vaccine was 0.95 and the GC content was 49.56%. Both these values indicate good expression of the vaccine construct might be expected. Cloning of the vaccine construct is mentioned in <xref rid="vaccines-11-00263-f007" ref-type="fig">Figure 7</xref>.</p>
      </sec>
      <sec id="sec3dot7-vaccines-11-00263">
        <title>3.7. Docking and Refinement</title>
        <p>Molecular docking analysis was carried out in order to analyze the binding mode of the vaccine construct with immune cell receptors (MHC-I, MHC-II and TLR-4). The patch dock web server generated the top 20 docked complexes as tabulated in <xref rid="app1-vaccines-11-00263" ref-type="app">Tables S2&#x2013;S4</xref>. The docked complexes were further refined using the fire docked webserver. The server generated the top 10 refined docked complexes as mentioned in <xref rid="vaccines-11-00263-t005" ref-type="table">Table 5</xref>, <xref rid="vaccines-11-00263-t006" ref-type="table">Table 6</xref> and <xref rid="vaccines-11-00263-t007" ref-type="table">Table 7</xref>. In the case of the vaccine-MHC-I complex, solution 1 was selected as it has the lowest global energy score of &#x2212;5.48 kcal/mol. The major energy contribution was seen from attractive van der Waals energy. For vaccine-MHC-II, solution 9 was opted as it has lowest global energy of 0.64 kcal/mol. Similarly, for the vaccine-TLR-4 complex, solution 7 was opted for with a net global energy score of &#x2212;2.69 kcal/mol. In all the selected complexes, it was found that the vaccine docked with receptors in a stable conformation and the vaccine antigens were exposed to and recognized by the host immune system. The intermolecular docked complexes are presented in <xref rid="vaccines-11-00263-f008" ref-type="fig">Figure 8</xref>.</p>
      </sec>
      <sec id="sec3dot8-vaccines-11-00263">
        <title>3.8. MDS Analysis</title>
        <p>MDS analysis was carried out to check the binding stability and dynamics of docked complexes. The docked complexes were investigated at 200 ns periods of time. The trajectories of the MDS consisted of RMSD and RMSF analyses [<xref rid="B100-vaccines-11-00263" ref-type="bibr">100</xref>,<xref rid="B101-vaccines-11-00263" ref-type="bibr">101</xref>]. As compared to vaccine-MHC-II and TLR-4, vaccine and MHC-I molecules showed stability as the graph is constant through the simulation time. The vaccine-MHC-II complex showed minor changes which may be due to loops present in the structure but towards the simulation end it became stable. Overall, the RMSD graph shows that there is proper conformational stability between vaccine and receptors molecules. The RMSD graph is presented in <xref rid="vaccines-11-00263-f009" ref-type="fig">Figure 9</xref>A. Similarly, residue base fluctuations were assessed through RMSF. In RMSF analysis, it was observed that the vaccine-MHC-II complex has proper stability as mentioned in <xref rid="vaccines-11-00263-f009" ref-type="fig">Figure 9</xref>B.</p>
      </sec>
      <sec id="sec3dot9-vaccines-11-00263">
        <title>3.9. Binding Free Energies Calculation</title>
        <p>The docking results were further validated using binding free energies calculations. The MMGB/PB/SA analysis was adopted for energy estimation. In MMGBSA analysis, &#x2212;259.48 kcal/mol, &#x2212;206.79 kcal/mol, &#x2212;215.73 kcal/mol delta energy were estimated for vaccine-TLR-4, vaccine-MHC-I and vaccine-MHC-II, respectively. Similarly, in MM-PBSA analysis, for vaccine-TLR-4, vaccine-MHC-I, and vaccine-MHC-II, a net energy of &#x2212;235.18 kcal/mol, &#x2212;206.79 kcal/mol and &#x2212;215.73 kcal/mol was calculated. Details of overall binding energies prediction are tabulated in <xref rid="vaccines-11-00263-t008" ref-type="table">Table 8</xref>.</p>
      </sec>
      <sec id="sec3dot10-vaccines-11-00263">
        <title>3.10. WaterSwap and Binding Entropy Calculation</title>
        <p>To revalidate the findings and provide more confidence regarding the vaccine&#x2019;s stable interactions with the receptors, water-swap calculations were performed. Three algorithms were used in the water-swap method i.e. thermodynamic integration, free energy perturbation and Bennetts. The water-swap calculations found highly stable energies for all three complexes [<xref rid="B97-vaccines-11-00263" ref-type="bibr">97</xref>,<xref rid="B102-vaccines-11-00263" ref-type="bibr">102</xref>,<xref rid="B103-vaccines-11-00263" ref-type="bibr">103</xref>]. For the TLR-4-vaccine complex, the water-swap estimations were: thermodynamic integration (&#x2212;46.5 kcal/mol); free energy perturbation (&#x2212;47.52 kcal/mol); and Bennetts (&#x2212;46.97 kcal/mol). The thermodynamic integration, free energy perturbation and Bennetts values for the MHC-I-vaccine complex were &#x2212;48.5 kcal/mol, &#x2212;47.0 kcal/mol and &#x2212;47.41 kcal/mol, respectively. Likewise, for the MHC-II-vaccine complex, the values were &#x2212;42.1 kcal/mol (thermodynamic integration), &#x2212;43.6 kcal/mol (free energy perturbation) and &#x2212;41.6 kcal/mol (Bennetts). All these values indicate good systems convergence and strong intermolecular affinity. Additionally, entropy energy indicates values of 45 kcal/mol for the TLR-4-vaccine complex, 51.87 kcal/mol for the MHC-I-vaccine complex, and 50.2 kcal/mol for the MHC-II-vaccine complex. These findings suggest that the vaccine has less physical freedom and docked well with the receptor for efficient immuen system recognition and processing.</p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="sec4-vaccines-11-00263">
      <title>4. Discussion</title>
      <p>In this study, nine proteins were prioritized as potential subunit vaccine candidate targets in the complete proteome of <italic toggle="yes">B. melitensis</italic> based on comprehensive investigation of comparative proteomics, subtractive proteomics, reverse vaccinology, immunoinformatic, and biophysics approaches. Furthermore, antigenic, non-allergic, non-toxic, and water-soluble epitopes were successfully predicted in the mentioned vaccine proteins. A multi-epitopes vaccine construct was built which revealed stable binding conformation and dynamics with different immune receptors such as TLR-4, MHC-I and MHC-II.</p>
      <p>The emergence of bacterial resistance to antibiotics is a serious threat to public health [<xref rid="B104-vaccines-11-00263" ref-type="bibr">104</xref>]. The resistance to antibiotics is alarming as efficacy of commercially available antibiotics is becoming less effective. Additionally, development of new antibiotics is of less interest due to several regulatory challenges faced by pharma companies [<xref rid="B105-vaccines-11-00263" ref-type="bibr">105</xref>]. This problem can be addressed by a vaccination process [<xref rid="B15-vaccines-11-00263" ref-type="bibr">15</xref>]. However not all vaccines are effective and helpful in prevention of infectious disease but somehow can reduce the level of infections [<xref rid="B106-vaccines-11-00263" ref-type="bibr">106</xref>,<xref rid="B107-vaccines-11-00263" ref-type="bibr">107</xref>]. The conventional Pasture vaccinology suffers from several limitations i.e., time consuming, development of unwanted immune responses, high cost, less efficacy and specificity, not applicable to non-cultivated microbes and less stability [<xref rid="B108-vaccines-11-00263" ref-type="bibr">108</xref>]. A huge amount of genomic data available in databases could help in identification of good vaccine candidates [<xref rid="B12-vaccines-11-00263" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-11-00263" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-11-00263" ref-type="bibr">14</xref>]. The use of reverse vaccinology, bioinformatics and immmunoinformatics approaches in recent times is an alternative way of designing vaccines against different pathogens [<xref rid="B11-vaccines-11-00263" ref-type="bibr">11</xref>,<xref rid="B15-vaccines-11-00263" ref-type="bibr">15</xref>,<xref rid="B109-vaccines-11-00263" ref-type="bibr">109</xref>]. We used pan-genome analysis, subtractive proteomics analysis immunoinformatics, and molecular docking and simulation methods for the designing of multi-epitopes-based vaccines against <italic toggle="yes">B. melitensis.</italic> The multi-epitopes vaccines consist of overlapping epitopes and are considered an ideal approach for prevention and treatment of infectious diseases [<xref rid="B107-vaccines-11-00263" ref-type="bibr">107</xref>]. The success of these vaccines has been elaborated by the EMD640744 vaccine that is currently under phase I clinical trials for advanced solid tumors [<xref rid="B107-vaccines-11-00263" ref-type="bibr">107</xref>]. These vaccines can generate humoral, cytotoxic and helper T-cell immune responses. They contain epitopes which can be recognized by multiple clones of TCRs and stimulate cellular and humoral immunity simultaneously [<xref rid="B107-vaccines-11-00263" ref-type="bibr">107</xref>]. They also have the ability to generate enhanced immunogenicity that is long term [<xref rid="B107-vaccines-11-00263" ref-type="bibr">107</xref>]. Additionally, they are free from unwanted antigens that lead to pathologically adverse reactions [<xref rid="B71-vaccines-11-00263" ref-type="bibr">71</xref>]. Through subtractive proteomics filters, 10 proteins were selected for B&#x2013;cell peptides prediction. These proteins were catalase, siderophore ABC transporter substrate-binding protein, pyridoxamine 5&#x2032;-phosphate oxidase, superoxide dismutase, peptidylprolyl isomerase, superoxide dismutase family protein, septation protein A, hypothetical protein, binding-protein-dependent transport systems inner membrane component, 4-hydroxy-2-oxoheptanedioate aldolase. The shortlisted proteins were utilized for B-cell and T-cell epitopes in the prediction and prioritization phases. With the help of several immunoinformatics approaches, WTNAEAEQV, EAEAKAEAE, EADAYYASR, GLEGKSLEE, KGFDAARVG, YAPEPQPQT, REISAAEGR, KSGVSGNRL, and ESDQTGSSP were prioritized as appropriate epitopes for multi-epitopes vaccine design. The epitopes were tested for antigenicity, allergenicity, toxicity, water solubility, and adhesion probability. Further, non-toxic, probable antigenic, good water-soluble and physiochemically stable epitopes were used in chimeric vaccine construction. The designed vaccine was then utilized for interaction studies with immune cell receptors as it was important to unveil for successful vaccine development. This was achieved by molecular docking that predicted the vaccine candidates&#x2019; stable interactions with MHC-I, MHC-II and TLR-4 and thus could evoke humoral and cellular immunity. Intermolecular docked stability of vaccine with immune cell receptors in dynamic environments is important for long-term antigen presenting and processing. The dynamic movement of the docked complexes revealed the vaccine candidates&#x2019; proper binding that can generate long-term immunity against the targeted pathogen.</p>
      <p>Brucellosis is estimated to cause 500,000 thousand cases each year. Among the Brucella genera, <italic toggle="yes">B. melitensis</italic> is the most pathogenic species and shows broad resistance to a spectrum of antibiotics especially rifampicin [<xref rid="B110-vaccines-11-00263" ref-type="bibr">110</xref>]. Therefore, efforts are needed for development of a safe and effective vaccine. In the recent past, several computational efforts have revealed potential vaccine candidates against different bacterial pathogens. A previous study conducted by Ismail, Ahmad and Azam, 2020, successfully predicted an in silico multi-epitopes vaccine against bacterial members of Enterobacteriaceae [<xref rid="B38-vaccines-11-00263" ref-type="bibr">38</xref>]. In another work, three distinct types of surface peptides were investigated that can effectively provoke the immune response (AtfC), (PMI2533) and (PMI1466) against <italic toggle="yes">Proteus mirabilis</italic> [<xref rid="B111-vaccines-11-00263" ref-type="bibr">111</xref>]. Furthermore, computer-aided vaccine-design studies against <italic toggle="yes">Pseudomonas aeruginosa</italic> [<xref rid="B46-vaccines-11-00263" ref-type="bibr">46</xref>], <italic toggle="yes">Providencia rettgeri</italic> [<xref rid="B112-vaccines-11-00263" ref-type="bibr">112</xref>], <italic toggle="yes">Streptococcus pneumoniae</italic> [<xref rid="B113-vaccines-11-00263" ref-type="bibr">113</xref>], and <italic toggle="yes">Klebsiella pneumoniae</italic> [<xref rid="B114-vaccines-11-00263" ref-type="bibr">114</xref>] have been successfully carried out in the recent past. The reverse vaccinology approach have also been applied to <italic toggle="yes">B. melitensis</italic>. However, those studies were not as comprehensive as that conducted herein. In one study, Omp10, Omp25, Omp31 and BtpB were used for epitopes prediction. The designed multi-epitopes vaccine comprised 806 amino acids that were used in different biophysics approaches [<xref rid="B115-vaccines-11-00263" ref-type="bibr">115</xref>]. In another work, Omp22, Omp28 and Omp19 were utilized for vaccine design [<xref rid="B116-vaccines-11-00263" ref-type="bibr">116</xref>].</p>
      <p>In silico vaccine design is rapidly emerging due to the wide range of genomic data available and development of new bioinformatics tools. These analyses are highly effective and provide new pathways for the synthesis of novel vaccines against resistant pathogens [<xref rid="B9-vaccines-11-00263" ref-type="bibr">9</xref>,<xref rid="B117-vaccines-11-00263" ref-type="bibr">117</xref>,<xref rid="B118-vaccines-11-00263" ref-type="bibr">118</xref>,<xref rid="B119-vaccines-11-00263" ref-type="bibr">119</xref>]. However, our study has a few limitations. The order of the epitopes in the designed vaccine must be evaluated for optimal biological potency [<xref rid="B38-vaccines-11-00263" ref-type="bibr">38</xref>]. The choice of delivery route and delivery system are also a challenge [<xref rid="B38-vaccines-11-00263" ref-type="bibr">38</xref>]. Detailed experimental testing is required to validate the immune potency of the designed vaccine against <italic toggle="yes">B. melitensis</italic>.</p>
    </sec>
    <sec sec-type="conclusions" id="sec5-vaccines-11-00263">
      <title>5. Conclusions</title>
      <p>In this computer-aided vaccine-design work, 10 proteins; catalase, siderophore ABC transporter substrate-binding protein, pyridoxamine 5&#x2032;-phosphate oxidase, superoxide dismutase, peptidylprolyl isomerase, superoxide dismutase family protein, septation protein A, hypothetical protein, binding-protein-dependent transport systems inner membrane component and 4-hydroxy-2-oxoheptanedioate aldolase were identified as promising vaccine targets selected for epitopes prediction against <italic toggle="yes">B. melitensis.</italic> The proteins were forecasted to harbor antigenic epitopes that were capable of eliciting strong humoral, cellular and helper immunological responses. Most of the mentioned targets were not predicted before and are novel in this respect. The designed chimeric multi-epitopes vaccine showed a robust interactions network with different immune receptors ensuring that the vaccine is capable of eliciting a variety of immunological reactions. The vaccine type is safe from allergic and reactogenic responses and accurate/specific in generating immunological response and memory. Further, the multi-epitopes vaccine will be easy to design and could provide better immunogenicity and antigenicity compared to single peptide vaccines. The vaccine construct may also provide experimentalists a ready framework to test vaccine epitopes in vivo and in vitro biological models and thus may speed up the development of a safe, effective and broad spectrum vaccine against <italic toggle="yes">B. melitensis</italic>.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p><bold>Disclaimer/Publisher&#x2019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p>
      </fn>
    </fn-group>
    <app-group>
      <app id="app1-vaccines-11-00263">
        <title>Supplementary Materials</title>
        <p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/vaccines11020263/s1">https://www.mdpi.com/article/10.3390/vaccines11020263/s1</uri>, Table S1. Predicted T-cells epitopes. Table S2. Top 20 docked complexes of vaccine and MHC-I molecules. Table S3. Top 20 docked complexes of vaccine and MHC-II molecule. Table S4. Top 20 docked complexes of vaccine and TLR-4 molecule.</p>
        <supplementary-material id="vaccines-11-00263-s001" position="float" content-type="local-data">
          <media xlink:href="vaccines-11-00263-s001.zip">
            <caption>
              <p>Click here for additional data file.</p>
            </caption>
          </media>
        </supplementary-material>
      </app>
    </app-group>
    <notes>
      <title>Author Contributions</title>
      <p>Conceptualization, S.A. and M.K.; methodology, M.M. and S.K.; software, M.M.; validation, A.U., M.u.H. and S.S.; formal analysis, A.I.A.-H.; investigation, M.M. and S.A.A.; resources, M.I.; data curation, M.M.; writing&#x2014;original draft preparation, M.M. and M.H.; writing&#x2014;review and editing, S.A.; visualization, M.K.; supervision, S.A.; project administration, S.A.; funding acquisition, S.A. All authors have read and agreed to the published version of the manuscript.</p>
    </notes>
    <notes>
      <title>Institutional Review Board Statement</title>
      <p>Not relevant to this study.</p>
    </notes>
    <notes>
      <title>Informed Consent Statement</title>
      <p>Not relevant to this study.</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Data Availability Statement</title>
      <p>All the data is available in this study. </p>
    </notes>
    <notes notes-type="COI-statement">
      <title>Conflicts of Interest</title>
      <p>The authors confirmed that there is no conflict of interest associated with the study and data reported in it. </p>
    </notes>
    <ref-list>
      <title>References</title>
      <ref id="B1-vaccines-11-00263">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Cani&#xE7;a</surname><given-names>M.</given-names></name>
<name><surname>Manageiro</surname><given-names>V.</given-names></name>
<name><surname>Abriouel</surname><given-names>H.</given-names></name>
<name><surname>Moran-Gilad</surname><given-names>J.</given-names></name>
<name><surname>Franz</surname><given-names>C.M.A.P.</given-names></name>
</person-group>
          <article-title>Antibiotic Resistance in Foodborne Bacteria</article-title>
          <source>Trends Food Sci. Technol.</source>
          <year>2019</year>
          <volume>84</volume>
          <fpage>41</fpage>
          <lpage>44</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tifs.2018.08.001</pub-id>
        </element-citation>
      </ref>
      <ref id="B2-vaccines-11-00263">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>MacLean</surname><given-names>R.C.</given-names></name>
<name><surname>San Millan</surname><given-names>A.</given-names></name>
</person-group>
          <article-title>The Evolution of Antibiotic Resistance</article-title>
          <source>Science</source>
          <year>2019</year>
          <volume>365</volume>
          <fpage>1082</fpage>
          <lpage>1083</lpage>
          <pub-id pub-id-type="doi">10.1126/science.aax3879</pub-id>
          <pub-id pub-id-type="pmid">31515374</pub-id>
        </element-citation>
      </ref>
      <ref id="B3-vaccines-11-00263">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Ventola</surname><given-names>C.L.</given-names></name>
</person-group>
          <article-title>The Antibiotic Resistance Crisis: Part 2: Management Strategies and New Agents</article-title>
          <source>Pharm. Ther.</source>
          <year>2015</year>
          <volume>40</volume>
          <fpage>344</fpage>
        </element-citation>
      </ref>
      <ref id="B4-vaccines-11-00263">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Masignani</surname><given-names>V.</given-names></name>
<name><surname>Pizza</surname><given-names>M.</given-names></name>
<name><surname>Moxon</surname><given-names>E.R.</given-names></name>
</person-group>
          <article-title>The Development of a Vaccine against Meningococcus B Using Reverse Vaccinology</article-title>
          <source>Front. Immunol.</source>
          <year>2019</year>
          <volume>10</volume>
          <fpage>751</fpage>
          <pub-id pub-id-type="doi">10.3389/fimmu.2019.00751</pub-id>
          <pub-id pub-id-type="pmid">31040844</pub-id>
        </element-citation>
      </ref>
      <ref id="B5-vaccines-11-00263">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Pollard</surname><given-names>A.J.</given-names></name>
<name><surname>Bijker</surname><given-names>E.M.</given-names></name>
</person-group>
          <article-title>A Guide to Vaccinology: From Basic Principles to New Developments</article-title>
          <source>Nat. Rev. Immunol.</source>
          <year>2021</year>
          <volume>21</volume>
          <fpage>83</fpage>
          <lpage>100</lpage>
          <pub-id pub-id-type="doi">10.1038/s41577-020-00479-7</pub-id>
          <pub-id pub-id-type="pmid">33353987</pub-id>
        </element-citation>
      </ref>
      <ref id="B6-vaccines-11-00263">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Clem</surname><given-names>A.S.</given-names></name>
</person-group>
          <article-title>Fundamentals of Vaccine Immunology</article-title>
          <source>J. Glob. Infect Dis.</source>
          <year>2011</year>
          <volume>3</volume>
          <fpage>73</fpage>
          <pub-id pub-id-type="doi">10.4103/0974-777X.77299</pub-id>
          <pub-id pub-id-type="pmid">21572612</pub-id>
        </element-citation>
      </ref>
      <ref id="B7-vaccines-11-00263">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Bidmos</surname><given-names>F.A.</given-names></name>
<name><surname>Siris</surname><given-names>S.</given-names></name>
<name><surname>Gladstone</surname><given-names>C.A.</given-names></name>
<name><surname>Langford</surname><given-names>P.R.</given-names></name>
</person-group>
          <article-title>Bacterial Vaccine Antigen Discovery in the Reverse Vaccinology 2.0 Era: Progress and Challenges</article-title>
          <source>Front. Immunol.</source>
          <year>2018</year>
          <volume>9</volume>
          <fpage>2315</fpage>
          <pub-id pub-id-type="doi">10.3389/fimmu.2018.02315</pub-id>
          <pub-id pub-id-type="pmid">30349542</pub-id>
        </element-citation>
      </ref>
      <ref id="B8-vaccines-11-00263">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Ahmad</surname><given-names>S.</given-names></name>
<name><surname>Shahid</surname><given-names>F.</given-names></name>
<name><surname>Tahir ul Qamar</surname><given-names>M.</given-names></name>
<name><surname>Abbasi</surname><given-names>S.W.</given-names></name>
<name><surname>Sajjad</surname><given-names>W.</given-names></name>
<name><surname>Ismail</surname><given-names>S.</given-names></name>
<name><surname>Alrumaihi</surname><given-names>F.</given-names></name>
<name><surname>Allemailem</surname><given-names>K.S.</given-names></name>
<name><surname>Almatroudi</surname><given-names>A.</given-names></name>
<name><surname>Ullah Saeed</surname><given-names>H.F.</given-names></name>
</person-group>
          <article-title>Immuno-Informatics Analysis of Pakistan-Based HCV Subtype-3a for Chimeric Polypeptide Vaccine Design</article-title>
          <source>Vaccines</source>
          <year>2021</year>
          <volume>9</volume>
          <elocation-id>293</elocation-id>
          <pub-id pub-id-type="doi">10.3390/vaccines9030293</pub-id>
          <pub-id pub-id-type="pmid">33801143</pub-id>
        </element-citation>
      </ref>
      <ref id="B9-vaccines-11-00263">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Dalsass</surname><given-names>M.</given-names></name>
<name><surname>Brozzi</surname><given-names>A.</given-names></name>
<name><surname>Medini</surname><given-names>D.</given-names></name>
<name><surname>Rappuoli</surname><given-names>R.</given-names></name>
</person-group>
          <article-title>Comparison of Open-Source Reverse Vaccinology Programs for Bacterial Vaccine Antigen Discovery</article-title>
          <source>Front. Immunol.</source>
          <year>2019</year>
          <volume>10</volume>
          <fpage>113</fpage>
          <pub-id pub-id-type="doi">10.3389/fimmu.2019.00113</pub-id>
          <pub-id pub-id-type="pmid">30837982</pub-id>
        </element-citation>
      </ref>
      <ref id="B10-vaccines-11-00263">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Abdullah</surname><given-names>M.</given-names></name>
<name><surname>Kadivella</surname><given-names>M.</given-names></name>
<name><surname>Sharma</surname><given-names>R.</given-names></name>
<name><surname>Faisal</surname><given-names>S.M.</given-names></name>
<name><surname>Azam</surname><given-names>S.</given-names></name>
</person-group>
          <article-title>Designing of Multiepitope-Based Vaccine against Leptospirosis Using Immuno-Informatics Approaches</article-title>
          <source>bioRxiv</source>
          <year>2021</year>
          <pub-id pub-id-type="doi">10.1101/2021.02.22.431920</pub-id>
        </element-citation>
      </ref>
      <ref id="B11-vaccines-11-00263">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Santos</surname><given-names>A.</given-names></name>
<name><surname>Ali</surname><given-names>A.</given-names></name>
<name><surname>Barbosa</surname><given-names>E.</given-names></name>
<name><surname>Silva</surname><given-names>A.</given-names></name>
<name><surname>Miyoshi</surname><given-names>A.</given-names></name>
<name><surname>Barh</surname><given-names>D.</given-names></name>
<name><surname>Azevedo</surname><given-names>V.</given-names></name>
</person-group>
          <article-title>The Reverse Vaccinology-A Contextual Overview</article-title>
          <source>IIOABJ</source>
          <year>2011</year>
          <volume>2</volume>
          <fpage>8</fpage>
          <lpage>15</lpage>
        </element-citation>
      </ref>
      <ref id="B12-vaccines-11-00263">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Rappuoli</surname><given-names>R.</given-names></name>
</person-group>
          <article-title>Reverse Vaccinology</article-title>
          <source>Curr. Opin. Microbiol.</source>
          <year>2000</year>
          <volume>3</volume>
          <fpage>445</fpage>
          <lpage>450</lpage>
          <pub-id pub-id-type="doi">10.1016/S1369-5274(00)00119-3</pub-id>
          <pub-id pub-id-type="pmid">11050440</pub-id>
        </element-citation>
      </ref>
      <ref id="B13-vaccines-11-00263">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Adu-Bobie</surname><given-names>J.</given-names></name>
<name><surname>Capecchi</surname><given-names>B.</given-names></name>
<name><surname>Serruto</surname><given-names>D.</given-names></name>
<name><surname>Rappuoli</surname><given-names>R.</given-names></name>
<name><surname>Pizza</surname><given-names>M.</given-names></name>
</person-group>
          <article-title>Two Years into Reverse Vaccinology</article-title>
          <source>Vaccine</source>
          <year>2003</year>
          <volume>21</volume>
          <fpage>605</fpage>
          <lpage>610</lpage>
          <pub-id pub-id-type="doi">10.1016/S0264-410X(02)00566-2</pub-id>
          <pub-id pub-id-type="pmid">12531326</pub-id>
        </element-citation>
      </ref>
      <ref id="B14-vaccines-11-00263">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Mora</surname><given-names>M.</given-names></name>
<name><surname>Veggi</surname><given-names>D.</given-names></name>
<name><surname>Santini</surname><given-names>L.</given-names></name>
<name><surname>Pizza</surname><given-names>M.</given-names></name>
<name><surname>Rappuoli</surname><given-names>R.</given-names></name>
</person-group>
          <article-title>Reverse Vaccinology</article-title>
          <source>Drug Discov. Today</source>
          <year>2003</year>
          <volume>8</volume>
          <fpage>459</fpage>
          <lpage>464</lpage>
          <pub-id pub-id-type="doi">10.1016/S1359-6446(03)02689-8</pub-id>
          <pub-id pub-id-type="pmid">12801798</pub-id>
        </element-citation>
      </ref>
      <ref id="B15-vaccines-11-00263">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Delany</surname><given-names>I.</given-names></name>
<name><surname>Rappuoli</surname><given-names>R.</given-names></name>
<name><surname>Seib</surname><given-names>K.L.</given-names></name>
</person-group>
          <article-title>Vaccines, Reverse Vaccinology, and Bacterial Pathogenesis</article-title>
          <source>Cold Spring Harb. Perspect. Med.</source>
          <year>2013</year>
          <volume>3</volume>
          <fpage>a012476</fpage>
          <pub-id pub-id-type="doi">10.1101/cshperspect.a012476</pub-id>
          <pub-id pub-id-type="pmid">23637311</pub-id>
        </element-citation>
      </ref>
      <ref id="B16-vaccines-11-00263">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Mazlan</surname><given-names>M.</given-names></name>
<name><surname>Khairani-Bejo</surname><given-names>S.</given-names></name>
<name><surname>Hamzah</surname><given-names>H.</given-names></name>
<name><surname>Nasruddin</surname><given-names>N.S.</given-names></name>
<name><surname>Salleh</surname><given-names>A.</given-names></name>
<name><surname>Zamri-Saad</surname><given-names>M.</given-names></name>
</person-group>
          <article-title>Pathological Changes, Distribution and Detection of Brucella Melitensis in Foetuses of Experimentally-Infected Does</article-title>
          <source>Vet. Q.</source>
          <year>2021</year>
          <volume>41</volume>
          <fpage>36</fpage>
          <lpage>49</lpage>
          <pub-id pub-id-type="doi">10.1080/01652176.2020.1867328</pub-id>
          <pub-id pub-id-type="pmid">33349157</pub-id>
        </element-citation>
      </ref>
      <ref id="B17-vaccines-11-00263">
        <label>17.</label>
        <element-citation publication-type="webpage">
          <person-group person-group-type="author">
<collab>World Organisation for Animal Health Brucellosis</collab>
</person-group>
          <article-title>(Brucella Abortus, B. Melitensis and B. Suis) (Infection with B. Abortus, B. Melitensis and B. Suis)</article-title>
          <source>Manual of Diagnostic Tests and Vaccines for Terrestrial Animals</source>
          <year>2016</year>
          <comment>Available online: <ext-link xlink:href="https://www.woah.org/fileadmin/Home/fr/Health_standards/tahm/3.01.04_BRUCELLOSIS.pdf" ext-link-type="uri">https://www.woah.org/fileadmin/Home/fr/Health_standards/tahm/3.01.04_BRUCELLOSIS.pdf</ext-link></comment>
          <date-in-citation content-type="access-date" iso-8601-date="2022-12-20">(accessed on 20 December 2022)</date-in-citation>
        </element-citation>
      </ref>
      <ref id="B18-vaccines-11-00263">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Mantur</surname><given-names>B.</given-names></name>
<name><surname>Amarnath</surname><given-names>S.</given-names></name>
<name><surname>Shinde</surname><given-names>R.</given-names></name>
</person-group>
          <article-title>Review of Clinical and Laboratory Features of Human Brucellosis</article-title>
          <source>Indian J. Med. Microbiol.</source>
          <year>2007</year>
          <volume>25</volume>
          <fpage>188</fpage>
          <lpage>202</lpage>
          <pub-id pub-id-type="doi">10.1016/S0255-0857(21)02105-8</pub-id>
          <pub-id pub-id-type="pmid">17901634</pub-id>
        </element-citation>
      </ref>
      <ref id="B19-vaccines-11-00263">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>de Figueiredo</surname><given-names>P.</given-names></name>
<name><surname>Ficht</surname><given-names>T.A.</given-names></name>
<name><surname>Rice-Ficht</surname><given-names>A.</given-names></name>
<name><surname>Rossetti</surname><given-names>C.A.</given-names></name>
<name><surname>Adams</surname><given-names>L.G.</given-names></name>
</person-group>
          <article-title>Pathogenesis and Immunobiology of Brucellosis: Review of Brucella--Host Interactions</article-title>
          <source>Am. J. Pathol.</source>
          <year>2015</year>
          <volume>185</volume>
          <fpage>1505</fpage>
          <lpage>1517</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ajpath.2015.03.003</pub-id>
          <pub-id pub-id-type="pmid">25892682</pub-id>
        </element-citation>
      </ref>
      <ref id="B20-vaccines-11-00263">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Ponsart</surname><given-names>C.</given-names></name>
<name><surname>Riou</surname><given-names>M.</given-names></name>
<name><surname>Locatelli</surname><given-names>Y.</given-names></name>
<name><surname>Jacques</surname><given-names>I.</given-names></name>
<name><surname>Fadeau</surname><given-names>A.</given-names></name>
<name><surname>Jay</surname><given-names>M.</given-names></name>
<name><surname>Simon</surname><given-names>R.</given-names></name>
<name><surname>Perrot</surname><given-names>L.</given-names></name>
<name><surname>Freddi</surname><given-names>L.</given-names></name>
<name><surname>Breton</surname><given-names>S.</given-names></name>
<etal/>
</person-group>
          <article-title>Brucella Melitensis Rev.1 Vaccination Generates a Higher Shedding Risk of the Vaccine Strain in Alpine Ibex (Capra Ibex) Compared to the Domestic Goat (Capra Hircus)</article-title>
          <source>Vet. Res.</source>
          <year>2019</year>
          <volume>50</volume>
          <fpage>1</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="doi">10.1186/s13567-019-0717-0</pub-id>
          <pub-id pub-id-type="pmid">30616664</pub-id>
        </element-citation>
      </ref>
      <ref id="B21-vaccines-11-00263">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Gonz&#xE1;lez</surname><given-names>D.</given-names></name>
<name><surname>Grill&#xF3;</surname><given-names>M.J.</given-names></name>
<name><surname>de Miguel</surname><given-names>M.J.</given-names></name>
<name><surname>Ali</surname><given-names>T.</given-names></name>
<name><surname>Arce-Gorvel</surname><given-names>V.</given-names></name>
<name><surname>Delrue</surname><given-names>R.M.</given-names></name>
<name><surname>Conde-&#xC1;lvarez</surname><given-names>R.</given-names></name>
<name><surname>Mu&#xF1;oz</surname><given-names>P.</given-names></name>
<name><surname>L&#xF3;pez-Go&#xF1;i</surname><given-names>I.</given-names></name>
<name><surname>Iriarte</surname><given-names>M.</given-names></name>
<etal/>
</person-group>
          <article-title>Brucellosis Vaccines: Assessment of Brucella Melitensis Lipopolysaccharide Rough Mutants Defective in Core and O-Polysaccharide Synthesis and Export</article-title>
          <source>PLoS ONE</source>
          <year>2008</year>
          <volume>3</volume>
          <elocation-id>e2760</elocation-id>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0002760</pub-id>
          <pub-id pub-id-type="pmid">18648644</pub-id>
        </element-citation>
      </ref>
      <ref id="B22-vaccines-11-00263">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Costa Oliveira</surname><given-names>S.</given-names></name>
<name><surname>Costa Macedo</surname><given-names>G.</given-names></name>
<name><surname>Augusto de Almeida</surname><given-names>L.</given-names></name>
<name><surname>Souza de Oliveira</surname><given-names>F.</given-names></name>
<name><surname>Onate</surname><given-names>A.</given-names></name>
<name><surname>Cassataro</surname><given-names>J.</given-names></name>
<name><surname>Hernan Giambartolomei</surname><given-names>G.</given-names></name>
</person-group>
          <article-title>Recent Advances in Understanding Immunity Against Brucellosis: Application for Vaccine Development</article-title>
          <source>Open Vet. Sci. J.</source>
          <year>2014</year>
          <volume>4</volume>
          <pub-id pub-id-type="doi">10.2174/1874318801004010102</pub-id>
        </element-citation>
      </ref>
      <ref id="B23-vaccines-11-00263">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Dorneles</surname><given-names>E.M.S.</given-names></name>
<name><surname>Sriranganathan</surname><given-names>N.</given-names></name>
<name><surname>Lage</surname><given-names>A.P.</given-names></name>
</person-group>
          <article-title>Recent Advances in Brucella Abortus Vaccines</article-title>
          <source>Vet. Res.</source>
          <year>2015</year>
          <volume>46</volume>
          <fpage>1</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="doi">10.1186/s13567-015-0199-7</pub-id>
          <pub-id pub-id-type="pmid">25582708</pub-id>
        </element-citation>
      </ref>
      <ref id="B24-vaccines-11-00263">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Yang</surname><given-names>X.</given-names></name>
<name><surname>Hudson</surname><given-names>M.</given-names></name>
<name><surname>Walters</surname><given-names>N.</given-names></name>
<name><surname>Bargatze</surname><given-names>R.F.</given-names></name>
<name><surname>Pascual</surname><given-names>D.W.</given-names></name>
</person-group>
          <article-title>Selection of Protective Epitopes for Brucella Melitensis by DNA Vaccination</article-title>
          <source>Infect. Immun.</source>
          <year>2005</year>
          <volume>73</volume>
          <fpage>7297</fpage>
          <lpage>7303</lpage>
          <pub-id pub-id-type="doi">10.1128/IAI.73.11.7297-7303.2005</pub-id>
          <pub-id pub-id-type="pmid">16239526</pub-id>
        </element-citation>
      </ref>
      <ref id="B25-vaccines-11-00263">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Mugunthan</surname><given-names>S.P.</given-names></name>
<name><surname>Harish</surname><given-names>M.C.</given-names></name>
</person-group>
          <article-title>Multi-Epitope-Based Vaccine Designed by Targeting Cytoadherence Proteins of Mycoplasma Gallisepticum</article-title>
          <source>ACS Omega</source>
          <year>2021</year>
          <volume>6</volume>
          <fpage>13742</fpage>
          <lpage>13755</lpage>
          <pub-id pub-id-type="doi">10.1021/acsomega.1c01032</pub-id>
          <pub-id pub-id-type="pmid">34095666</pub-id>
        </element-citation>
      </ref>
      <ref id="B26-vaccines-11-00263">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Adeoti</surname><given-names>O.M.</given-names></name>
</person-group>
          <article-title>Prediction of Multi-Epitopic Domains of a Putative Oral Vaccine against Hepatitis C Virus</article-title>
          <source>Int. J. Immunol. Microbiol.</source>
          <year>2021</year>
          <volume>1</volume>
          <fpage>16</fpage>
          <lpage>22</lpage>
          <pub-id pub-id-type="doi">10.55124/ijim.v1i1.39</pub-id>
        </element-citation>
      </ref>
      <ref id="B27-vaccines-11-00263">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Ud-Din</surname><given-names>M.</given-names></name>
<name><surname>Albutti</surname><given-names>A.</given-names></name>
<name><surname>Ullah</surname><given-names>A.</given-names></name>
<name><surname>Ismail</surname><given-names>S.</given-names></name>
<name><surname>Ahmad</surname><given-names>S.</given-names></name>
<name><surname>Naz</surname><given-names>A.</given-names></name>
<name><surname>Khurram</surname><given-names>M.</given-names></name>
<name><surname>Haq</surname><given-names>M.</given-names></name>
<name><surname>Afsheen</surname><given-names>Z.</given-names></name>
<name><surname>Bakri</surname><given-names>Y.</given-names></name>
<etal/>
</person-group>
          <article-title>Vaccinomics to Design a Multi-Epitopes Vaccine for Acinetobacter Baumannii</article-title>
          <source>Int. J. Environ. Res. Public Health</source>
          <year>2022</year>
          <volume>19</volume>
          <elocation-id>5568</elocation-id>
          <pub-id pub-id-type="doi">10.3390/ijerph19095568</pub-id>
          <pub-id pub-id-type="pmid">35564967</pub-id>
        </element-citation>
      </ref>
      <ref id="B28-vaccines-11-00263">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Fatima</surname><given-names>I.</given-names></name>
<name><surname>Ahmad</surname><given-names>S.</given-names></name>
<name><surname>Abbasi</surname><given-names>S.W.</given-names></name>
<name><surname>Ashfaq</surname><given-names>U.A.</given-names></name>
<name><surname>Shahid</surname><given-names>F.</given-names></name>
<name><surname>ul Qamar</surname><given-names>M.T.</given-names></name>
<name><surname>Rehman</surname><given-names>A.</given-names></name>
<name><surname>Allemailem</surname><given-names>K.S.</given-names></name>
</person-group>
          <article-title>Designing of a Multi-Epitopes-Based Peptide Vaccine against Rift Valley Fever Virus and Its Validation through Integrated Computational Approaches</article-title>
          <source>Comput. Biol. Med.</source>
          <year>2022</year>
          <volume>141</volume>
          <fpage>105151</fpage>
          <pub-id pub-id-type="doi">10.1016/j.compbiomed.2021.105151</pub-id>
          <pub-id pub-id-type="pmid">34942394</pub-id>
        </element-citation>
      </ref>
      <ref id="B29-vaccines-11-00263">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Ismail</surname><given-names>S.</given-names></name>
<name><surname>Abbasi</surname><given-names>S.W.</given-names></name>
<name><surname>Yousaf</surname><given-names>M.</given-names></name>
<name><surname>Ahmad</surname><given-names>S.</given-names></name>
<name><surname>Muhammad</surname><given-names>K.</given-names></name>
<name><surname>Waheed</surname><given-names>Y.</given-names></name>
</person-group>
          <article-title>Design of a Multi-Epitopes Vaccine against Hantaviruses: An Immunoinformatics and Molecular Modelling Approach</article-title>
          <source>Vaccines</source>
          <year>2022</year>
          <volume>10</volume>
          <elocation-id>378</elocation-id>
          <pub-id pub-id-type="doi">10.3390/vaccines10030378</pub-id>
          <pub-id pub-id-type="pmid">35335010</pub-id>
        </element-citation>
      </ref>
      <ref id="B30-vaccines-11-00263">
        <label>30.</label>
        <element-citation publication-type="webpage">
          <person-group person-group-type="author">
<name><surname>Omoniyi</surname><given-names>A.A.</given-names></name>
<name><surname>Adebisi</surname><given-names>S.S.</given-names></name>
<name><surname>Musa</surname><given-names>S.A.</given-names></name>
<name><surname>Nzalak</surname><given-names>J.O.</given-names></name>
<name><surname>Danborno</surname><given-names>B.</given-names></name>
<name><surname>Bauchi</surname><given-names>Z.M.</given-names></name>
<name><surname>Badmus</surname><given-names>I.T.</given-names></name>
<name><surname>Olatomide</surname><given-names>O.D.</given-names></name>
<name><surname>Oladimeji</surname><given-names>O.J.</given-names></name>
<name><surname>Nyengaard</surname><given-names>J.R.</given-names></name>
</person-group>
          <article-title>Immunoinformatics Analysis and In-Silico Design of Multi-Epitopes Vaccine Against Lassa Virus</article-title>
          <year>2021</year>
          <comment>Available online: <ext-link xlink:href="https://assets.researchsquare.com/files/rs-355782/v1/9bf6a115-7a8a-4638-a451-8d0a7330b307.pdf?c=1637244600" ext-link-type="uri">https://assets.researchsquare.com/files/rs-355782/v1/9bf6a115-7a8a-4638-a451-8d0a7330b307.pdf?c=1637244600</ext-link></comment>
          <date-in-citation content-type="access-date" iso-8601-date="2022-12-22">(accessed on 22 December 2022)</date-in-citation>
        </element-citation>
      </ref>
      <ref id="B31-vaccines-11-00263">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Alharbi</surname><given-names>M.</given-names></name>
<name><surname>Alshammari</surname><given-names>A.</given-names></name>
<name><surname>Alasmari</surname><given-names>A.F.</given-names></name>
<name><surname>Alharbi</surname><given-names>S.M.</given-names></name>
<name><surname>ul Qamar</surname><given-names>M.</given-names></name>
<name><surname>Ullah</surname><given-names>A.</given-names></name>
<name><surname>Ahmad</surname><given-names>S.</given-names></name>
<name><surname>Irfan</surname><given-names>M.</given-names></name>
<name><surname>Khalil</surname><given-names>A.A.K.</given-names></name>
</person-group>
          <article-title>Designing of a Recombinant Multi-Epitopes Based Vaccine against Enterococcus Mundtii Using Bioinformatics and Immunoinformatics Approaches</article-title>
          <source>Int. J. Environ. Res. Public Health</source>
          <year>2022</year>
          <volume>19</volume>
          <elocation-id>3729</elocation-id>
          <pub-id pub-id-type="doi">10.3390/ijerph19063729</pub-id>
          <pub-id pub-id-type="pmid">35329417</pub-id>
        </element-citation>
      </ref>
      <ref id="B32-vaccines-11-00263">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Rida</surname><given-names>T.</given-names></name>
<name><surname>Ahmad</surname><given-names>S.</given-names></name>
<name><surname>Ullah</surname><given-names>A.</given-names></name>
<name><surname>Ismail</surname><given-names>S.</given-names></name>
<name><surname>Tahir ul Qamar</surname><given-names>M.</given-names></name>
<name><surname>Afsheen</surname><given-names>Z.</given-names></name>
<name><surname>Khurram</surname><given-names>M.</given-names></name>
<name><surname>Saqib Ishaq</surname><given-names>M.</given-names></name>
<name><surname>Alkhathami</surname><given-names>A.G.</given-names></name>
<name><surname>Alatawi</surname><given-names>E.A.</given-names></name>
</person-group>
          <article-title>Pan-Genome Analysis of Oral Bacterial Pathogens to Predict a Potential Novel Multi-Epitopes Vaccine Candidate</article-title>
          <source>Int. J. Environ. Res. Public Health</source>
          <year>2022</year>
          <volume>19</volume>
          <elocation-id>8408</elocation-id>
          <pub-id pub-id-type="doi">10.3390/ijerph19148408</pub-id>
          <pub-id pub-id-type="pmid">35886259</pub-id>
        </element-citation>
      </ref>
      <ref id="B33-vaccines-11-00263">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Ullah</surname><given-names>A.</given-names></name>
<name><surname>Ahmad</surname><given-names>S.</given-names></name>
<name><surname>Ismail</surname><given-names>S.</given-names></name>
<name><surname>Afsheen</surname><given-names>Z.</given-names></name>
<name><surname>Khurram</surname><given-names>M.</given-names></name>
<name><surname>Tahir ul Qamar</surname><given-names>M.</given-names></name>
<name><surname>AlSuhaymi</surname><given-names>N.</given-names></name>
<name><surname>Alsugoor</surname><given-names>M.H.</given-names></name>
<name><surname>Allemailem</surname><given-names>K.S.</given-names></name>
</person-group>
          <article-title>Towards A Novel Multi-Epitopes Chimeric Vaccine for Simulating Strong Immune Responses and Protection against Morganella Morganii</article-title>
          <source>Int. J. Environ. Res. Public Health</source>
          <year>2021</year>
          <volume>18</volume>
          <elocation-id>10961</elocation-id>
          <pub-id pub-id-type="doi">10.3390/ijerph182010961</pub-id>
          <pub-id pub-id-type="pmid">34682706</pub-id>
        </element-citation>
      </ref>
      <ref id="B34-vaccines-11-00263">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Coordinators</surname><given-names>N.R.</given-names></name>
</person-group>
          <article-title>Database Resources of the National Center for Biotechnology Information</article-title>
          <source>Nucleic Acids Res.</source>
          <year>2017</year>
          <volume>45</volume>
          <fpage>D12</fpage>
          <pub-id pub-id-type="pmid">27899561</pub-id>
        </element-citation>
      </ref>
      <ref id="B35-vaccines-11-00263">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Chaudhari</surname><given-names>N.M.</given-names></name>
<name><surname>Gupta</surname><given-names>V.K.</given-names></name>
<name><surname>Dutta</surname><given-names>C.</given-names></name>
</person-group>
          <article-title>BPGA-an Ultra-Fast Pan-Genome Analysis Pipeline</article-title>
          <source>Sci. Rep.</source>
          <year>2016</year>
          <volume>6</volume>
          <fpage>24373</fpage>
          <pub-id pub-id-type="doi">10.1038/srep24373</pub-id>
          <pub-id pub-id-type="pmid">27071527</pub-id>
        </element-citation>
      </ref>
      <ref id="B36-vaccines-11-00263">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Sajjad</surname><given-names>R.</given-names></name>
<name><surname>Ahmad</surname><given-names>S.</given-names></name>
<name><surname>Azam</surname><given-names>S.S.</given-names></name>
</person-group>
          <article-title>In Silico Screening of Antigenic B-Cell Derived T-Cell Epitopes and Designing of a Multi-Epitope Peptide Vaccine for Acinetobacter Nosocomialis</article-title>
          <source>J. Mol. Graph. Model</source>
          <year>2020</year>
          <volume>94</volume>
          <fpage>107477</fpage>
          <pub-id pub-id-type="doi">10.1016/j.jmgm.2019.107477</pub-id>
          <pub-id pub-id-type="pmid">31654980</pub-id>
        </element-citation>
      </ref>
      <ref id="B37-vaccines-11-00263">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Ahmad</surname><given-names>S.</given-names></name>
<name><surname>Azam</surname><given-names>S.S.</given-names></name>
</person-group>
          <article-title>A Novel Approach of Virulome Based Reverse Vaccinology for Exploring and Validating Peptide-Based Vaccine Candidates against the Most Troublesome Nosocomial Pathogen: Acinetobacter Baumannii</article-title>
          <source>J. Mol. Graph. Model</source>
          <year>2018</year>
          <volume>83</volume>
          <fpage>1</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jmgm.2018.04.020</pub-id>
          <pub-id pub-id-type="pmid">29753164</pub-id>
        </element-citation>
      </ref>
      <ref id="B38-vaccines-11-00263">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Ismail</surname><given-names>S.</given-names></name>
<name><surname>Ahmad</surname><given-names>S.</given-names></name>
<name><surname>Azam</surname><given-names>S.S.</given-names></name>
</person-group>
          <article-title>Vaccinomics to Design a Novel Single Chimeric Subunit Vaccine for Broad-Spectrum Immunological Applications Targeting Nosocomial Enterobacteriaceae Pathogens</article-title>
          <source>Eur. J. Pharm. Sci.</source>
          <year>2020</year>
          <volume>146</volume>
          <fpage>105258</fpage>
          <pub-id pub-id-type="doi">10.1016/j.ejps.2020.105258</pub-id>
          <pub-id pub-id-type="pmid">32035109</pub-id>
        </element-citation>
      </ref>
      <ref id="B39-vaccines-11-00263">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Ismail</surname><given-names>S.</given-names></name>
<name><surname>Ahmad</surname><given-names>S.</given-names></name>
<name><surname>Azam</surname><given-names>S.S.</given-names></name>
</person-group>
          <article-title>Immunoinformatics Characterization of SARS-CoV-2 Spike Glycoprotein for Prioritization of Epitope Based Multivalent Peptide Vaccine</article-title>
          <source>J. Mol. Liq.</source>
          <year>2020</year>
          <volume>314</volume>
          <fpage>113612</fpage>
          <pub-id pub-id-type="doi">10.1016/j.molliq.2020.113612</pub-id>
          <pub-id pub-id-type="pmid">32834259</pub-id>
        </element-citation>
      </ref>
      <ref id="B40-vaccines-11-00263">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Sanober</surname><given-names>G.</given-names></name>
<name><surname>Ahmad</surname><given-names>S.</given-names></name>
<name><surname>Azam</surname><given-names>S.S.</given-names></name>
</person-group>
          <article-title>Identification of Plausible Drug Targets by Investigating the Druggable Genome of MDR Staphylococcus Epidermidis</article-title>
          <source>Gene Rep.</source>
          <year>2017</year>
          <volume>7</volume>
          <fpage>147</fpage>
          <lpage>153</lpage>
          <pub-id pub-id-type="doi">10.1016/j.genrep.2017.04.008</pub-id>
        </element-citation>
      </ref>
      <ref id="B41-vaccines-11-00263">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Huang</surname><given-names>Y.</given-names></name>
<name><surname>Niu</surname><given-names>B.</given-names></name>
<name><surname>Gao</surname><given-names>Y.</given-names></name>
<name><surname>Fu</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
</person-group>
          <article-title>CD-HIT Suite: A Web Server for Clustering and Comparing Biological Sequences</article-title>
          <source>Bioinformatics</source>
          <year>2010</year>
          <volume>26</volume>
          <fpage>680</fpage>
          <lpage>682</lpage>
          <pub-id pub-id-type="doi">10.1093/bioinformatics/btq003</pub-id>
          <pub-id pub-id-type="pmid">20053844</pub-id>
        </element-citation>
      </ref>
      <ref id="B42-vaccines-11-00263">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Fu</surname><given-names>L.</given-names></name>
<name><surname>Niu</surname><given-names>B.</given-names></name>
<name><surname>Zhu</surname><given-names>Z.</given-names></name>
<name><surname>Wu</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
</person-group>
          <article-title>CD-HIT: Accelerated for Clustering the next-Generation Sequencing Data</article-title>
          <source>Bioinformatics</source>
          <year>2012</year>
          <volume>28</volume>
          <fpage>3150</fpage>
          <lpage>3152</lpage>
          <pub-id pub-id-type="doi">10.1093/bioinformatics/bts565</pub-id>
          <pub-id pub-id-type="pmid">23060610</pub-id>
        </element-citation>
      </ref>
      <ref id="B43-vaccines-11-00263">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Godzik</surname><given-names>A.</given-names></name>
</person-group>
          <article-title>Cd-Hit: A Fast Program for Clustering and Comparing Large Sets of Protein or Nucleotide Sequences</article-title>
          <source>Bioinformatics</source>
          <year>2006</year>
          <volume>22</volume>
          <fpage>1658</fpage>
          <lpage>1659</lpage>
          <pub-id pub-id-type="doi">10.1093/bioinformatics/btl158</pub-id>
          <pub-id pub-id-type="pmid">16731699</pub-id>
        </element-citation>
      </ref>
      <ref id="B44-vaccines-11-00263">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Abbas</surname><given-names>G.</given-names></name>
<name><surname>Zafar</surname><given-names>I.</given-names></name>
<name><surname>Ahmad</surname><given-names>S.</given-names></name>
<name><surname>Azam</surname><given-names>S.S.</given-names></name>
</person-group>
          <article-title>Immunoinformatics Design of a Novel Multi-Epitope Peptide Vaccine to Combat Multi-Drug Resistant Infections Caused by Vibrio Vulnificus</article-title>
          <source>Eur. J. Pharm. Sci.</source>
          <year>2020</year>
          <volume>142</volume>
          <fpage>105160</fpage>
          <pub-id pub-id-type="doi">10.1016/j.ejps.2019.105160</pub-id>
          <pub-id pub-id-type="pmid">31751777</pub-id>
        </element-citation>
      </ref>
      <ref id="B45-vaccines-11-00263">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Ahmad</surname><given-names>S.</given-names></name>
<name><surname>Raza</surname><given-names>S.</given-names></name>
<name><surname>Uddin</surname><given-names>R.</given-names></name>
<name><surname>Azam</surname><given-names>S.S.</given-names></name>
</person-group>
          <article-title>Comparative Subtractive Proteomics Based Ranking for Antibiotic Targets against the Dirtiest Superbug: Acinetobacter Baumannii</article-title>
          <source>J. Mol. Graph. Model</source>
          <year>2018</year>
          <volume>82</volume>
          <fpage>74</fpage>
          <lpage>92</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jmgm.2018.04.005</pub-id>
          <pub-id pub-id-type="pmid">29705560</pub-id>
        </element-citation>
      </ref>
      <ref id="B46-vaccines-11-00263">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Rashid</surname><given-names>M.I.</given-names></name>
<name><surname>Naz</surname><given-names>A.</given-names></name>
<name><surname>Ali</surname><given-names>A.</given-names></name>
<name><surname>Andleeb</surname><given-names>S.</given-names></name>
</person-group>
          <article-title>Prediction of Vaccine Candidates against Pseudomonas Aeruginosa: An Integrated Genomics and Proteomics Approach</article-title>
          <source>Genomics</source>
          <year>2017</year>
          <volume>109</volume>
          <fpage>274</fpage>
          <lpage>283</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ygeno.2017.05.001</pub-id>
          <pub-id pub-id-type="pmid">28487172</pub-id>
        </element-citation>
      </ref>
      <ref id="B47-vaccines-11-00263">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Naz</surname><given-names>K.</given-names></name>
<name><surname>Naz</surname><given-names>A.</given-names></name>
<name><surname>Ashraf</surname><given-names>S.T.</given-names></name>
<name><surname>Rizwan</surname><given-names>M.</given-names></name>
<name><surname>Ahmad</surname><given-names>J.</given-names></name>
<name><surname>Baumbach</surname><given-names>J.</given-names></name>
<name><surname>Ali</surname><given-names>A.</given-names></name>
</person-group>
          <article-title>PanRV: Pangenome-Reverse Vaccinology Approach for Identifications of Potential Vaccine Candidates in Microbial Pangenome</article-title>
          <source>BMC Bioinform.</source>
          <year>2019</year>
          <volume>20</volume>
          <elocation-id>123</elocation-id>
          <pub-id pub-id-type="doi">10.1186/s12859-019-2713-9</pub-id>
          <pub-id pub-id-type="pmid">30871454</pub-id>
        </element-citation>
      </ref>
      <ref id="B48-vaccines-11-00263">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Rizwan</surname><given-names>M.</given-names></name>
<name><surname>Naz</surname><given-names>A.</given-names></name>
<name><surname>Ahmad</surname><given-names>J.</given-names></name>
<name><surname>Naz</surname><given-names>K.</given-names></name>
<name><surname>Obaid</surname><given-names>A.</given-names></name>
<name><surname>Parveen</surname><given-names>T.</given-names></name>
<name><surname>Ahsan</surname><given-names>M.</given-names></name>
<name><surname>Ali</surname><given-names>A.</given-names></name>
</person-group>
          <article-title>VacSol: A High Throughput in Silico Pipeline to Predict Potential Therapeutic Targets in Prokaryotic Pathogens Using Subtractive Reverse Vaccinology</article-title>
          <source>BMC Bioinform.</source>
          <year>2017</year>
          <volume>18</volume>
          <elocation-id>106</elocation-id>
          <pub-id pub-id-type="doi">10.1186/s12859-017-1540-0</pub-id>
        </element-citation>
      </ref>
      <ref id="B49-vaccines-11-00263">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Yu</surname><given-names>N.Y.</given-names></name>
<name><surname>Wagner</surname><given-names>J.R.</given-names></name>
<name><surname>Laird</surname><given-names>M.R.</given-names></name>
<name><surname>Melli</surname><given-names>G.</given-names></name>
<name><surname>Rey</surname><given-names>S.</given-names></name>
<name><surname>Lo</surname><given-names>R.</given-names></name>
<name><surname>Dao</surname><given-names>P.</given-names></name>
<name><surname>Sahinalp</surname><given-names>S.C.</given-names></name>
<name><surname>Ester</surname><given-names>M.</given-names></name>
<name><surname>Foster</surname><given-names>L.J.</given-names></name>
<etal/>
</person-group>
          <article-title>PSORTb 3.0: Improved Protein Subcellular Localization Prediction with Refined Localization Subcategories and Predictive Capabilities for All Prokaryotes</article-title>
          <source>Bioinformatics</source>
          <year>2010</year>
          <volume>26</volume>
          <fpage>1608</fpage>
          <lpage>1615</lpage>
          <pub-id pub-id-type="doi">10.1093/bioinformatics/btq249</pub-id>
          <pub-id pub-id-type="pmid">20472543</pub-id>
        </element-citation>
      </ref>
      <ref id="B50-vaccines-11-00263">
        <label>50.</label>
        <element-citation publication-type="gov">
          <person-group person-group-type="author">
<name><surname>Blast</surname><given-names>N.</given-names></name>
</person-group>
          <article-title>Basic Local Alignment Search Tool. National Library of Medicine: National Center for Biotechnology Information</article-title>
          <year>2015</year>
          <comment>Available online: <ext-link xlink:href="https://blast.ncbi.nlm.nih.gov/Blast.cgi" ext-link-type="uri">https://blast.ncbi.nlm.nih.gov/Blast.cgi</ext-link></comment>
          <date-in-citation content-type="access-date" iso-8601-date="2022-12-20">(accessed on 20 December 2022)</date-in-citation>
        </element-citation>
      </ref>
      <ref id="B51-vaccines-11-00263">
        <label>51.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Naz</surname><given-names>K.</given-names></name>
<name><surname>Ullah</surname><given-names>N.</given-names></name>
<name><surname>Naz</surname><given-names>A.</given-names></name>
<name><surname>Irum</surname><given-names>S.</given-names></name>
<name><surname>Dar</surname><given-names>H.A.</given-names></name>
<name><surname>Zaheer</surname><given-names>T.</given-names></name>
<name><surname>Shahid</surname><given-names>F.</given-names></name>
<name><surname>Ali</surname><given-names>A.</given-names></name>
</person-group>
          <article-title>The Epidemiological and Pangenome Landscape of Staphylococcus Aureus and Identification of Conserved Novel Candidate Vaccine Antigens</article-title>
          <source>Curr. Proteom.</source>
          <year>2022</year>
          <volume>19</volume>
          <fpage>114</fpage>
          <lpage>126</lpage>
          <pub-id pub-id-type="doi">10.2174/1570164618666210212122847</pub-id>
        </element-citation>
      </ref>
      <ref id="B52-vaccines-11-00263">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Ahmad</surname><given-names>S.</given-names></name>
<name><surname>Ranaghan</surname><given-names>K.E.</given-names></name>
<name><surname>Azam</surname><given-names>S.S.</given-names></name>
</person-group>
          <article-title>Combating Tigecycline Resistant Acinetobacter Baumannii: A Leap Forward towards Multi-Epitope Based Vaccine Discovery</article-title>
          <source>Eur. J. Pharm. Sci.</source>
          <year>2019</year>
          <volume>132</volume>
          <fpage>1</fpage>
          <lpage>17</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejps.2019.02.023</pub-id>
          <pub-id pub-id-type="pmid">30797936</pub-id>
        </element-citation>
      </ref>
      <ref id="B53-vaccines-11-00263">
        <label>53.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Ma</surname><given-names>J.</given-names></name>
<name><surname>Qiu</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Ji</surname><given-names>Q.</given-names></name>
<name><surname>Xu</surname><given-names>D.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Wu</surname><given-names>Z.</given-names></name>
<name><surname>Liu</surname><given-names>Q.</given-names></name>
</person-group>
          <article-title>A Novel Design of Multi-Epitope Vaccine Against Helicobacter Pylori by Immunoinformatics Approach</article-title>
          <source>Int. J. Pept. Res. Ther.</source>
          <year>2021</year>
          <volume>27</volume>
          <fpage>1027</fpage>
          <lpage>1042</lpage>
          <pub-id pub-id-type="doi">10.1007/s10989-020-10148-x</pub-id>
          <pub-id pub-id-type="pmid">33424523</pub-id>
        </element-citation>
      </ref>
      <ref id="B54-vaccines-11-00263">
        <label>54.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Yu</surname><given-names>J.</given-names></name>
<name><surname>Yao</surname><given-names>Z.</given-names></name>
<name><surname>Sun</surname><given-names>L.</given-names></name>
<name><surname>Shen</surname><given-names>Y.</given-names></name>
<name><surname>Jin</surname><given-names>Q.</given-names></name>
</person-group>
          <article-title>VFDB: A Reference Database for Bacterial Virulence Factors</article-title>
          <source>Nucleic Acids Res.</source>
          <year>2005</year>
          <volume>33</volume>
          <fpage>D325</fpage>
          <lpage>D328</lpage>
          <pub-id pub-id-type="doi">10.1093/nar/gki008</pub-id>
          <pub-id pub-id-type="pmid">15608208</pub-id>
        </element-citation>
      </ref>
      <ref id="B55-vaccines-11-00263">
        <label>55.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Baseer</surname><given-names>S.</given-names></name>
<name><surname>Ahmad</surname><given-names>S.</given-names></name>
<name><surname>Ranaghan</surname><given-names>K.E.</given-names></name>
<name><surname>Azam</surname><given-names>S.S.</given-names></name>
</person-group>
          <article-title>Towards a Peptide-Based Vaccine against Shigella Sonnei: A Subtractive Reverse Vaccinology Based Approach</article-title>
          <source>Biologicals</source>
          <year>2017</year>
          <volume>50</volume>
          <fpage>87</fpage>
          <lpage>99</lpage>
          <pub-id pub-id-type="doi">10.1016/j.biologicals.2017.08.004</pub-id>
          <pub-id pub-id-type="pmid">28826780</pub-id>
        </element-citation>
      </ref>
      <ref id="B56-vaccines-11-00263">
        <label>56.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Asad</surname><given-names>Y.</given-names></name>
<name><surname>Ahmad</surname><given-names>S.</given-names></name>
<name><surname>Rungrotmongkol</surname><given-names>T.</given-names></name>
<name><surname>Ranaghan</surname><given-names>K.E.</given-names></name>
<name><surname>Azam</surname><given-names>S.S.</given-names></name>
</person-group>
          <article-title>Immuno-Informatics Driven Proteome-Wide Investigation Revealed Novel Peptide-Based Vaccine Targets against Emerging Multiple Drug Resistant Providencia Stuartii</article-title>
          <source>J. Mol. Graph. Model</source>
          <year>2018</year>
          <volume>80</volume>
          <fpage>238</fpage>
          <lpage>250</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jmgm.2018.01.010</pub-id>
          <pub-id pub-id-type="pmid">29414043</pub-id>
        </element-citation>
      </ref>
      <ref id="B57-vaccines-11-00263">
        <label>57.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
<name><surname>ProtParam</surname><given-names>E.</given-names></name>
</person-group>
          <source>ExPASy-ProtParam Tool</source>
          <publisher-name>SIB</publisher-name>
          <publisher-loc>Lausanne, Switzerland</publisher-loc>
          <year>2017</year>
        </element-citation>
      </ref>
      <ref id="B58-vaccines-11-00263">
        <label>58.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Albekairi</surname><given-names>T.H.</given-names></name>
<name><surname>Alshammari</surname><given-names>A.</given-names></name>
<name><surname>Alharbi</surname><given-names>M.</given-names></name>
<name><surname>Alshammary</surname><given-names>A.F.</given-names></name>
<name><surname>Tahir ul Qamar</surname><given-names>M.</given-names></name>
<name><surname>Ullah</surname><given-names>A.</given-names></name>
<name><surname>Irfan</surname><given-names>M.</given-names></name>
<name><surname>Ahmad</surname><given-names>S.</given-names></name>
</person-group>
          <article-title>Designing of a Novel Multi-Antigenic Epitope-Based Vaccine against E. Hormaechei: An Intergraded Reverse Vaccinology and Immunoinformatics Approach</article-title>
          <source>Vaccines</source>
          <year>2022</year>
          <volume>10</volume>
          <elocation-id>665</elocation-id>
          <pub-id pub-id-type="doi">10.3390/vaccines10050665</pub-id>
          <pub-id pub-id-type="pmid">35632421</pub-id>
        </element-citation>
      </ref>
      <ref id="B59-vaccines-11-00263">
        <label>59.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Tusnady</surname><given-names>G.E.</given-names></name>
<name><surname>Simon</surname><given-names>I.</given-names></name>
</person-group>
          <article-title>The HMMTOP Transmembrane Topology Prediction Server</article-title>
          <source>Bioinformatics</source>
          <year>2001</year>
          <volume>17</volume>
          <fpage>849</fpage>
          <lpage>850</lpage>
          <pub-id pub-id-type="doi">10.1093/bioinformatics/17.9.849</pub-id>
          <pub-id pub-id-type="pmid">11590105</pub-id>
        </element-citation>
      </ref>
      <ref id="B60-vaccines-11-00263">
        <label>60.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Yu</surname><given-names>P.</given-names></name>
<name><surname>Luo</surname><given-names>J.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.</given-names></name>
</person-group>
          <article-title>Secreted Protein Prediction System Combining CJ-SPHMM, TMHMM, and PSORT</article-title>
          <source>Mamm. Genome</source>
          <year>2003</year>
          <volume>14</volume>
          <fpage>859</fpage>
          <lpage>865</lpage>
          <pub-id pub-id-type="doi">10.1007/s00335-003-2296-6</pub-id>
          <pub-id pub-id-type="pmid">14724739</pub-id>
        </element-citation>
      </ref>
      <ref id="B61-vaccines-11-00263">
        <label>61.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>W.</given-names></name>
<name><surname>Negre</surname><given-names>N.N.</given-names></name>
<name><surname>White</surname><given-names>K.P.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Shah</surname><given-names>P.K.</given-names></name>
</person-group>
          <article-title>Determinants of Antigenicity and Specificity in Immune Response for Protein Sequences</article-title>
          <source>BMC Bioinform.</source>
          <year>2011</year>
          <volume>12</volume>
          <fpage>1</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="doi">10.1186/1471-2105-12-251</pub-id>
          <pub-id pub-id-type="pmid">21693021</pub-id>
        </element-citation>
      </ref>
      <ref id="B62-vaccines-11-00263">
        <label>62.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Doytchinova</surname><given-names>I.A.</given-names></name>
<name><surname>Flower</surname><given-names>D.R.</given-names></name>
</person-group>
          <article-title>VaxiJen: A Server for Prediction of Protective Antigens, Tumour Antigens and Subunit Vaccines</article-title>
          <source>BMC Bioinform.</source>
          <year>2007</year>
          <volume>8</volume>
          <elocation-id>4</elocation-id>
          <pub-id pub-id-type="doi">10.1186/1471-2105-8-4</pub-id>
          <pub-id pub-id-type="pmid">17207271</pub-id>
        </element-citation>
      </ref>
      <ref id="B63-vaccines-11-00263">
        <label>63.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Bonilla</surname><given-names>F.A.</given-names></name>
<name><surname>Oettgen</surname><given-names>H.C.</given-names></name>
</person-group>
          <article-title>Adaptive Immunity</article-title>
          <source>J. Allergy Clin. Immunol.</source>
          <year>2010</year>
          <volume>125</volume>
          <fpage>S33</fpage>
          <lpage>S40</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jaci.2009.09.017</pub-id>
          <pub-id pub-id-type="pmid">20061006</pub-id>
        </element-citation>
      </ref>
      <ref id="B64-vaccines-11-00263">
        <label>64.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>He</surname><given-names>Y.</given-names></name>
<name><surname>Xiang</surname><given-names>Z.</given-names></name>
<name><surname>Mobley</surname><given-names>H.L.T.</given-names></name>
</person-group>
          <article-title>Vaxign: The First Web-Based Vaccine Design Program for Reverse Vaccinology and Applications for Vaccine Development</article-title>
          <source>Biomed. Res. Int.</source>
          <year>2010</year>
          <volume>2010</volume>
          <fpage>297505</fpage>
          <pub-id pub-id-type="doi">10.1155/2010/297505</pub-id>
        </element-citation>
      </ref>
      <ref id="B65-vaccines-11-00263">
        <label>65.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Dimitrov</surname><given-names>I.</given-names></name>
<name><surname>Flower</surname><given-names>D.R.</given-names></name>
<name><surname>Doytchinova</surname><given-names>I.</given-names></name>
</person-group>
          <article-title>AllerTOP-a Server for in Silico Prediction of Allergens</article-title>
          <source>BMC Bioinform.</source>
          <year>2013</year>
          <volume>14</volume>
          <elocation-id>S4</elocation-id>
          <pub-id pub-id-type="doi">10.1186/1471-2105-14-S6-S4</pub-id>
          <pub-id pub-id-type="pmid">23735058</pub-id>
        </element-citation>
      </ref>
      <ref id="B66-vaccines-11-00263">
        <label>66.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Dhanda</surname><given-names>S.K.</given-names></name>
<name><surname>Mahajan</surname><given-names>S.</given-names></name>
<name><surname>Paul</surname><given-names>S.</given-names></name>
<name><surname>Yan</surname><given-names>Z.</given-names></name>
<name><surname>Kim</surname><given-names>H.</given-names></name>
<name><surname>Jespersen</surname><given-names>M.C.</given-names></name>
<name><surname>Jurtz</surname><given-names>V.</given-names></name>
<name><surname>Andreatta</surname><given-names>M.</given-names></name>
<name><surname>Greenbaum</surname><given-names>J.A.</given-names></name>
<name><surname>Marcatili</surname><given-names>P.</given-names></name>
</person-group>
          <article-title>IEDB-AR: Immune Epitope Database&#x2014;Analysis Resource in 2019</article-title>
          <source>Nucleic Acids Res.</source>
          <year>2019</year>
          <volume>47</volume>
          <fpage>W502</fpage>
          <lpage>W506</lpage>
          <pub-id pub-id-type="doi">10.1093/nar/gkz452</pub-id>
          <pub-id pub-id-type="pmid">31114900</pub-id>
        </element-citation>
      </ref>
      <ref id="B67-vaccines-11-00263">
        <label>67.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Guan</surname><given-names>P.</given-names></name>
<name><surname>Doytchinova</surname><given-names>I.A.</given-names></name>
<name><surname>Zygouri</surname><given-names>C.</given-names></name>
<name><surname>Flower</surname><given-names>D.R.</given-names></name>
</person-group>
          <article-title>MHCPred: A Server for Quantitative Prediction of Peptide--MHC Binding</article-title>
          <source>Nucleic Acids Res.</source>
          <year>2003</year>
          <volume>31</volume>
          <fpage>3621</fpage>
          <lpage>3624</lpage>
          <pub-id pub-id-type="doi">10.1093/nar/gkg510</pub-id>
          <pub-id pub-id-type="pmid">12824380</pub-id>
        </element-citation>
      </ref>
      <ref id="B68-vaccines-11-00263">
        <label>68.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Naz</surname><given-names>A.</given-names></name>
<name><surname>Awan</surname><given-names>F.M.</given-names></name>
<name><surname>Obaid</surname><given-names>A.</given-names></name>
<name><surname>Muhammad</surname><given-names>S.A.</given-names></name>
<name><surname>Paracha</surname><given-names>R.Z.</given-names></name>
<name><surname>Ahmad</surname><given-names>J.</given-names></name>
<name><surname>Ali</surname><given-names>A.</given-names></name>
</person-group>
          <article-title>Identification of Putative Vaccine Candidates against Helicobacter Pylori Exploiting Exoproteome and Secretome: A Reverse Vaccinology Based Approach</article-title>
          <source>Infect. Genet. Evol.</source>
          <year>2015</year>
          <volume>32</volume>
          <fpage>280</fpage>
          <lpage>291</lpage>
          <pub-id pub-id-type="doi">10.1016/j.meegid.2015.03.027</pub-id>
          <pub-id pub-id-type="pmid">25818402</pub-id>
        </element-citation>
      </ref>
      <ref id="B69-vaccines-11-00263">
        <label>69.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Garg</surname><given-names>A.</given-names></name>
<name><surname>Gupta</surname><given-names>D.</given-names></name>
</person-group>
          <article-title>VirulentPred: A SVM Based Prediction Method for Virulent Proteins in Bacterial Pathogens</article-title>
          <source>BMC Bioinform.</source>
          <year>2008</year>
          <volume>9</volume>
          <elocation-id>62</elocation-id>
          <pub-id pub-id-type="doi">10.1186/1471-2105-9-62</pub-id>
          <pub-id pub-id-type="pmid">18226234</pub-id>
        </element-citation>
      </ref>
      <ref id="B70-vaccines-11-00263">
        <label>70.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>S.</given-names></name>
<name><surname>Kapoor</surname><given-names>P.</given-names></name>
<name><surname>Chaudhary</surname><given-names>K.</given-names></name>
<name><surname>Gautam</surname><given-names>A.</given-names></name>
<name><surname>Kumar</surname><given-names>R.</given-names></name>
<name><surname>Raghava</surname><given-names>G.P.S.</given-names></name>
</person-group>
          <article-title>Peptide Toxicity Prediction</article-title>
          <source>Computational Peptidology</source>
          <publisher-name>Springer</publisher-name>
          <publisher-loc>Cham, Switzerland</publisher-loc>
          <year>2015</year>
          <fpage>143</fpage>
          <lpage>157</lpage>
        </element-citation>
      </ref>
      <ref id="B71-vaccines-11-00263">
        <label>71.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Malonis</surname><given-names>R.J.</given-names></name>
<name><surname>Lai</surname><given-names>J.R.</given-names></name>
<name><surname>Vergnolle</surname><given-names>O.</given-names></name>
</person-group>
          <article-title>Peptide-Based Vaccines: Current Progress and Future Challenges</article-title>
          <source>Chem. Rev.</source>
          <year>2019</year>
          <volume>120</volume>
          <fpage>3210</fpage>
          <lpage>3229</lpage>
          <pub-id pub-id-type="doi">10.1021/acs.chemrev.9b00472</pub-id>
          <pub-id pub-id-type="pmid">31804810</pub-id>
        </element-citation>
      </ref>
      <ref id="B72-vaccines-11-00263">
        <label>72.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Reche</surname><given-names>P.A.</given-names></name>
<name><surname>Fernandez-Caldas</surname><given-names>E.</given-names></name>
<name><surname>Flower</surname><given-names>D.R.</given-names></name>
<name><surname>Fridkis-Hareli</surname><given-names>M.</given-names></name>
<name><surname>Hoshino</surname><given-names>Y.</given-names></name>
</person-group>
          <article-title>Peptide-Based Immunotherapeutics and Vaccines</article-title>
          <source>J. Immunol. Res.</source>
          <year>2014</year>
          <volume>2014</volume>
          <fpage>256784</fpage>
          <pub-id pub-id-type="doi">10.1155/2014/256784</pub-id>
          <pub-id pub-id-type="pmid">24741581</pub-id>
        </element-citation>
      </ref>
      <ref id="B73-vaccines-11-00263">
        <label>73.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Alshammari</surname><given-names>A.</given-names></name>
<name><surname>Alharbi</surname><given-names>M.</given-names></name>
<name><surname>Alghamdi</surname><given-names>A.</given-names></name>
<name><surname>Alharbi</surname><given-names>S.A.</given-names></name>
<name><surname>Ashfaq</surname><given-names>U.A.</given-names></name>
<name><surname>Tahir ul Qamar</surname><given-names>M.</given-names></name>
<name><surname>Ullah</surname><given-names>A.</given-names></name>
<name><surname>Irfan</surname><given-names>M.</given-names></name>
<name><surname>Khan</surname><given-names>A.</given-names></name>
<name><surname>Ahmad</surname><given-names>S.</given-names></name>
</person-group>
          <article-title>Computer-Aided Multi-Epitope Vaccine Design against Enterobacter Xiangfangensis</article-title>
          <source>Int. J. Environ. Res. Public Health</source>
          <year>2022</year>
          <volume>19</volume>
          <elocation-id>7723</elocation-id>
          <pub-id pub-id-type="doi">10.3390/ijerph19137723</pub-id>
          <pub-id pub-id-type="pmid">35805383</pub-id>
        </element-citation>
      </ref>
      <ref id="B74-vaccines-11-00263">
        <label>74.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Baldauf</surname><given-names>K.J.</given-names></name>
<name><surname>Royal</surname><given-names>J.M.</given-names></name>
<name><surname>Hamorsky</surname><given-names>K.T.</given-names></name>
<name><surname>Matoba</surname><given-names>N.</given-names></name>
</person-group>
          <article-title>Cholera Toxin B: One Subunit with Many Pharmaceutical Applications</article-title>
          <source>Toxins</source>
          <year>2015</year>
          <volume>7</volume>
          <fpage>974</fpage>
          <lpage>996</lpage>
          <pub-id pub-id-type="doi">10.3390/toxins7030974</pub-id>
          <pub-id pub-id-type="pmid">25802972</pub-id>
        </element-citation>
      </ref>
      <ref id="B75-vaccines-11-00263">
        <label>75.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Stratmann</surname><given-names>T.</given-names></name>
</person-group>
          <article-title>Cholera Toxin Subunit B as Adjuvant----an Accelerator in Protective Immunity and a Break in Autoimmunity</article-title>
          <source>Vaccines</source>
          <year>2015</year>
          <volume>3</volume>
          <fpage>579</fpage>
          <lpage>596</lpage>
          <pub-id pub-id-type="doi">10.3390/vaccines3030579</pub-id>
          <pub-id pub-id-type="pmid">26350596</pub-id>
        </element-citation>
      </ref>
      <ref id="B76-vaccines-11-00263">
        <label>76.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Antonio-Herrera</surname><given-names>L.</given-names></name>
<name><surname>Badillo-Godinez</surname><given-names>O.</given-names></name>
<name><surname>Medina-Contreras</surname><given-names>O.</given-names></name>
<name><surname>Tepale-Segura</surname><given-names>A.</given-names></name>
<name><surname>Garc&#xED;a-Lozano</surname><given-names>A.</given-names></name>
<name><surname>Gutierrez-Xicotencatl</surname><given-names>L.</given-names></name>
<name><surname>Soldevila</surname><given-names>G.</given-names></name>
<name><surname>Esquivel-Guadarrama</surname><given-names>F.R.</given-names></name>
<name><surname>Idoyaga</surname><given-names>J.</given-names></name>
<name><surname>Bonifaz</surname><given-names>L.C.</given-names></name>
</person-group>
          <article-title>The Nontoxic Cholera B Subunit Is a Potent Adjuvant for Intradermal DC-Targeted Vaccination</article-title>
          <source>Front. Immunol.</source>
          <year>2018</year>
          <volume>9</volume>
          <fpage>2212</fpage>
          <pub-id pub-id-type="doi">10.3389/fimmu.2018.02212</pub-id>
          <pub-id pub-id-type="pmid">30319653</pub-id>
        </element-citation>
      </ref>
      <ref id="B77-vaccines-11-00263">
        <label>77.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>J.</given-names></name>
<name><surname>Randall</surname><given-names>A.Z.</given-names></name>
<name><surname>Sweredoski</surname><given-names>M.J.</given-names></name>
<name><surname>Baldi</surname><given-names>P.</given-names></name>
</person-group>
          <article-title>SCRATCH: A Protein Structure and Structural Feature Prediction Server</article-title>
          <source>Nucleic Acids Res.</source>
          <year>2005</year>
          <volume>33</volume>
          <fpage>W72</fpage>
          <lpage>W76</lpage>
          <pub-id pub-id-type="doi">10.1093/nar/gki396</pub-id>
          <pub-id pub-id-type="pmid">15980571</pub-id>
        </element-citation>
      </ref>
      <ref id="B78-vaccines-11-00263">
        <label>78.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Ko</surname><given-names>J.</given-names></name>
<name><surname>Park</surname><given-names>H.</given-names></name>
<name><surname>Heo</surname><given-names>L.</given-names></name>
<name><surname>Seok</surname><given-names>C.</given-names></name>
</person-group>
          <article-title>GalaxyWEB Server for Protein Structure Prediction and Refinement</article-title>
          <source>Nucleic Acids Res.</source>
          <year>2012</year>
          <volume>40</volume>
          <fpage>W294</fpage>
          <lpage>W297</lpage>
          <pub-id pub-id-type="doi">10.1093/nar/gks493</pub-id>
          <pub-id pub-id-type="pmid">22649060</pub-id>
        </element-citation>
      </ref>
      <ref id="B79-vaccines-11-00263">
        <label>79.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Heo</surname><given-names>L.</given-names></name>
<name><surname>Park</surname><given-names>H.</given-names></name>
<name><surname>Seok</surname><given-names>C.</given-names></name>
</person-group>
          <article-title>GalaxyRefine: Protein Structure Refinement Driven by Side-Chain Repacking</article-title>
          <source>Nucleic Acids Res.</source>
          <year>2013</year>
          <volume>41</volume>
          <fpage>W384</fpage>
          <lpage>W388</lpage>
          <pub-id pub-id-type="doi">10.1093/nar/gkt458</pub-id>
          <pub-id pub-id-type="pmid">23737448</pub-id>
        </element-citation>
      </ref>
      <ref id="B80-vaccines-11-00263">
        <label>80.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Craig</surname><given-names>D.B.</given-names></name>
<name><surname>Dombkowski</surname><given-names>A.A.</given-names></name>
</person-group>
          <article-title>Disulfide by Design 2.0: A Web-Based Tool for Disulfide Engineering in Proteins</article-title>
          <source>BMC Bioinform.</source>
          <year>2013</year>
          <volume>14</volume>
          <elocation-id>346</elocation-id>
          <pub-id pub-id-type="doi">10.1186/1471-2105-14-346</pub-id>
          <pub-id pub-id-type="pmid">24289175</pub-id>
        </element-citation>
      </ref>
      <ref id="B81-vaccines-11-00263">
        <label>81.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Grote</surname><given-names>A.</given-names></name>
<name><surname>Hiller</surname><given-names>K.</given-names></name>
<name><surname>Scheer</surname><given-names>M.</given-names></name>
<name><surname>M&#xFC;nch</surname><given-names>R.</given-names></name>
<name><surname>N&#xF6;rtemann</surname><given-names>B.</given-names></name>
<name><surname>Hempel</surname><given-names>D.C.</given-names></name>
<name><surname>Jahn</surname><given-names>D.</given-names></name>
</person-group>
          <article-title>JCat: A Novel Tool to Adapt Codon Usage of a Target Gene to Its Potential Expression Host</article-title>
          <source>Nucleic Acids Res.</source>
          <year>2005</year>
          <volume>33</volume>
          <fpage>W526</fpage>
          <lpage>W531</lpage>
          <pub-id pub-id-type="doi">10.1093/nar/gki376</pub-id>
          <pub-id pub-id-type="pmid">15980527</pub-id>
        </element-citation>
      </ref>
      <ref id="B82-vaccines-11-00263">
        <label>82.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Ahmad</surname><given-names>S.</given-names></name>
<name><surname>Navid</surname><given-names>A.</given-names></name>
<name><surname>Farid</surname><given-names>R.</given-names></name>
<name><surname>Abbas</surname><given-names>G.</given-names></name>
<name><surname>Ahmad</surname><given-names>F.</given-names></name>
<name><surname>Zaman</surname><given-names>N.</given-names></name>
<name><surname>Parvaiz</surname><given-names>N.</given-names></name>
<name><surname>Azam</surname><given-names>S.S.</given-names></name>
</person-group>
          <article-title>Design of a Novel Multi Epitope-Based Vaccine for Pandemic Coronavirus Disease (COVID-19) by Vaccinomics and Probable Prevention Strategy against Avenging Zoonotics</article-title>
          <source>Eur. J. Pharm. Sci.</source>
          <year>2020</year>
          <volume>151</volume>
          <fpage>105387</fpage>
          <pub-id pub-id-type="doi">10.1016/j.ejps.2020.105387</pub-id>
          <pub-id pub-id-type="pmid">32454128</pub-id>
        </element-citation>
      </ref>
      <ref id="B83-vaccines-11-00263">
        <label>83.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
<name><surname>Morris</surname><given-names>G.M.</given-names></name>
<name><surname>Lim-Wilby</surname><given-names>M.</given-names></name>
</person-group>
          <article-title>Molecular Docking</article-title>
          <source>Molecular Modeling of Proteins</source>
          <publisher-name>Springer</publisher-name>
          <publisher-loc>Cham, Switzerland</publisher-loc>
          <year>2008</year>
          <fpage>365</fpage>
          <lpage>382</lpage>
        </element-citation>
      </ref>
      <ref id="B84-vaccines-11-00263">
        <label>84.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Schneidman-Duhovny</surname><given-names>D.</given-names></name>
<name><surname>Inbar</surname><given-names>Y.</given-names></name>
<name><surname>Nussinov</surname><given-names>R.</given-names></name>
<name><surname>Wolfson</surname><given-names>H.J.</given-names></name>
</person-group>
          <article-title>PatchDock and SymmDock: Servers for Rigid and Symmetric Docking</article-title>
          <source>Nucleic Acids Res.</source>
          <year>2005</year>
          <volume>33</volume>
          <fpage>W363</fpage>
          <lpage>W367</lpage>
          <pub-id pub-id-type="doi">10.1093/nar/gki481</pub-id>
          <pub-id pub-id-type="pmid">15980490</pub-id>
        </element-citation>
      </ref>
      <ref id="B85-vaccines-11-00263">
        <label>85.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Andrusier</surname><given-names>N.</given-names></name>
<name><surname>Nussinov</surname><given-names>R.</given-names></name>
<name><surname>Wolfson</surname><given-names>H.J.</given-names></name>
</person-group>
          <article-title>FireDock: Fast Interaction Refinement in Molecular Docking</article-title>
          <source>Proteins Struct. Funct. Bioinform.</source>
          <year>2007</year>
          <volume>69</volume>
          <fpage>139</fpage>
          <lpage>159</lpage>
          <pub-id pub-id-type="doi">10.1002/prot.21495</pub-id>
        </element-citation>
      </ref>
      <ref id="B86-vaccines-11-00263">
        <label>86.</label>
        <element-citation publication-type="webpage">
          <person-group person-group-type="author">
<name><surname>Kaliappan</surname><given-names>S.</given-names></name>
<name><surname>Bombay</surname><given-names>I.I.T.</given-names></name>
</person-group>
          <article-title>UCSF Chimera-Overview</article-title>
          <year>2018</year>
          <comment>Available online: <ext-link xlink:href="http://doer.col.org/handle/123456789/9120" ext-link-type="uri">http://doer.col.org/handle/123456789/9120</ext-link></comment>
          <date-in-citation content-type="access-date" iso-8601-date="2022-10-16">(accessed on 16 October 2022)</date-in-citation>
        </element-citation>
      </ref>
      <ref id="B87-vaccines-11-00263">
        <label>87.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Hansson</surname><given-names>T.</given-names></name>
<name><surname>Oostenbrink</surname><given-names>C.</given-names></name>
<name><surname>van Gunsteren</surname><given-names>W.</given-names></name>
</person-group>
          <article-title>Molecular Dynamics Simulations</article-title>
          <source>Curr. Opin. Struct. Biol.</source>
          <year>2002</year>
          <volume>12</volume>
          <fpage>190</fpage>
          <lpage>196</lpage>
          <pub-id pub-id-type="doi">10.1016/S0959-440X(02)00308-1</pub-id>
          <pub-id pub-id-type="pmid">11959496</pub-id>
        </element-citation>
      </ref>
      <ref id="B88-vaccines-11-00263">
        <label>88.</label>
        <element-citation publication-type="webpage">
          <person-group person-group-type="author">
<name><surname>Case</surname><given-names>D.A.</given-names></name>
<name><surname>Belfon</surname><given-names>K.</given-names></name>
<name><surname>Ben-Shalom</surname><given-names>I.</given-names></name>
<name><surname>Brozell</surname><given-names>S.R.</given-names></name>
<name><surname>Cerutti</surname><given-names>D.</given-names></name>
<name><surname>Cheatham</surname><given-names>T.</given-names></name>
<name><surname>Cruzeiro</surname><given-names>V.W.D.</given-names></name>
<name><surname>Darden</surname><given-names>T.</given-names></name>
<name><surname>Duke</surname><given-names>R.E.</given-names></name>
<name><surname>Giambasu</surname><given-names>G.</given-names></name>
<etal/>
</person-group>
          <article-title>Amber 2020</article-title>
          <comment>Available online: <ext-link xlink:href="https://ambermd.org/doc12/Amber20.pdf" ext-link-type="uri">https://ambermd.org/doc12/Amber20.pdf</ext-link></comment>
          <date-in-citation content-type="access-date" iso-8601-date="2022-12-23">(accessed on 23 December 2022)</date-in-citation>
        </element-citation>
      </ref>
      <ref id="B89-vaccines-11-00263">
        <label>89.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
<name><surname>Kerrigan</surname><given-names>J.E.</given-names></name>
</person-group>
          <source>AMBER 10.0 Introductory Tutorial</source>
          <publisher-name>Citeseer</publisher-name>
          <publisher-loc>Princeton, NJ, USA</publisher-loc>
          <year>2009</year>
        </element-citation>
      </ref>
      <ref id="B90-vaccines-11-00263">
        <label>90.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Case</surname><given-names>D.A.</given-names></name>
<name><surname>Babin</surname><given-names>V.</given-names></name>
<name><surname>Berryman</surname><given-names>J.T.</given-names></name>
<name><surname>Betz</surname><given-names>R.M.</given-names></name>
<name><surname>Cai</surname><given-names>Q.</given-names></name>
<name><surname>Cerutti</surname><given-names>D.S.</given-names></name>
<name><surname>Cheatham</surname><given-names>T.E.</given-names><suffix>III</suffix></name>
<name><surname>Darden</surname><given-names>T.A.</given-names></name>
<name><surname>Duke</surname><given-names>R.E.</given-names></name>
<name><surname>Gohlke</surname><given-names>H.</given-names></name>
<etal/>
</person-group>
          <article-title>The FF14SB Force Field</article-title>
          <source>Amber</source>
          <year>2014</year>
          <volume>14</volume>
          <fpage>29</fpage>
          <lpage>31</lpage>
        </element-citation>
      </ref>
      <ref id="B91-vaccines-11-00263">
        <label>91.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Kr&#xE4;utler</surname><given-names>V.</given-names></name>
<name><surname>van Gunsteren</surname><given-names>W.F.</given-names></name>
<name><surname>H&#xFC;nenberger</surname><given-names>P.H.</given-names></name>
</person-group>
          <article-title>A Fast SHAKE Algorithm to Solve Distance Constraint Equations for Small Molecules in Molecular Dynamics Simulations</article-title>
          <source>J. Comput. Chem.</source>
          <year>2001</year>
          <volume>22</volume>
          <fpage>501</fpage>
          <lpage>508</lpage>
          <pub-id pub-id-type="doi">10.1002/1096-987X(20010415)22:5&lt;501::AID-JCC1021&gt;3.0.CO;2-V</pub-id>
        </element-citation>
      </ref>
      <ref id="B92-vaccines-11-00263">
        <label>92.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Roe</surname><given-names>D.R.</given-names></name>
<name><surname>Cheatham</surname><given-names>T.E.</given-names><suffix>III</suffix></name>
</person-group>
          <article-title>PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data</article-title>
          <source>J. Chem. Theory Comput.</source>
          <year>2013</year>
          <volume>9</volume>
          <fpage>3084</fpage>
          <lpage>3095</lpage>
          <pub-id pub-id-type="doi">10.1021/ct400341p</pub-id>
          <pub-id pub-id-type="pmid">26583988</pub-id>
        </element-citation>
      </ref>
      <ref id="B93-vaccines-11-00263">
        <label>93.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
<name><surname>Turner</surname><given-names>P.J.</given-names></name>
</person-group>
          <source>XMGRACE, Version 5.1. 19. Center for Coastal and Land-Margin Research</source>
          <publisher-name>Oregon Graduate Institute of Science and Technology</publisher-name>
          <publisher-loc>Beaverton, OR, USA</publisher-loc>
          <year>2005</year>
        </element-citation>
      </ref>
      <ref id="B94-vaccines-11-00263">
        <label>94.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Miller</surname><given-names>B.R.</given-names></name>
<name><surname>McGee</surname><given-names>T.D.</given-names></name>
<name><surname>Swails</surname><given-names>J.M.</given-names></name>
<name><surname>Homeyer</surname><given-names>N.</given-names></name>
<name><surname>Gohlke</surname><given-names>H.</given-names></name>
<name><surname>Roitberg</surname><given-names>A.E.</given-names></name>
</person-group>
          <article-title>MMPBSA.Py: An Efficient Program for End-State Free Energy Calculations</article-title>
          <source>J. Chem. Theory Comput.</source>
          <year>2012</year>
          <volume>8</volume>
          <fpage>3314</fpage>
          <lpage>3321</lpage>
          <pub-id pub-id-type="doi">10.1021/ct300418h</pub-id>
          <pub-id pub-id-type="pmid">26605738</pub-id>
        </element-citation>
      </ref>
      <ref id="B95-vaccines-11-00263">
        <label>95.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Sahakyan</surname><given-names>H.</given-names></name>
</person-group>
          <article-title>Improving Virtual Screening Results with MM/GBSA and MM/PBSA Rescoring</article-title>
          <source>J. Comput Aided Mol. Des.</source>
          <year>2021</year>
          <volume>35</volume>
          <fpage>731</fpage>
          <lpage>736</lpage>
          <pub-id pub-id-type="doi">10.1007/s10822-021-00389-3</pub-id>
          <pub-id pub-id-type="pmid">33983518</pub-id>
        </element-citation>
      </ref>
      <ref id="B96-vaccines-11-00263">
        <label>96.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Genheden</surname><given-names>S.</given-names></name>
<name><surname>Ryde</surname><given-names>U.</given-names></name>
</person-group>
          <article-title>The MM/PBSA and MM/GBSA Methods to Estimate Ligand-Binding Affinities</article-title>
          <source>Expert Opin. Drug Discov.</source>
          <year>2015</year>
          <volume>10</volume>
          <fpage>449</fpage>
          <lpage>461</lpage>
          <pub-id pub-id-type="doi">10.1517/17460441.2015.1032936</pub-id>
          <pub-id pub-id-type="pmid">25835573</pub-id>
        </element-citation>
      </ref>
      <ref id="B97-vaccines-11-00263">
        <label>97.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Woods</surname><given-names>C.J.</given-names></name>
<name><surname>Malaisree</surname><given-names>M.</given-names></name>
<name><surname>Hannongbua</surname><given-names>S.</given-names></name>
<name><surname>Mulholland</surname><given-names>A.J.</given-names></name>
</person-group>
          <article-title>A Water-Swap Reaction Coordinate for the Calculation of Absolute Protein-Ligand Binding Free Energies</article-title>
          <source>J. Chem. Phys.</source>
          <year>2011</year>
          <volume>134</volume>
          <fpage>054114</fpage>
          <pub-id pub-id-type="doi">10.1063/1.3519057</pub-id>
          <pub-id pub-id-type="pmid">21303099</pub-id>
        </element-citation>
      </ref>
      <ref id="B98-vaccines-11-00263">
        <label>98.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Genheden</surname><given-names>S.</given-names></name>
<name><surname>Kuhn</surname><given-names>O.</given-names></name>
<name><surname>Mikulskis</surname><given-names>P.</given-names></name>
<name><surname>Hoffmann</surname><given-names>D.</given-names></name>
<name><surname>Ryde</surname><given-names>U.</given-names></name>
</person-group>
          <article-title>The Normal-Mode Entropy in the MM/GBSA Method: Effect of System Truncation, Buffer Region, and Dielectric Constant</article-title>
          <source>J. Chem. Inf. Model</source>
          <year>2012</year>
          <volume>52</volume>
          <fpage>2079</fpage>
          <lpage>2088</lpage>
          <pub-id pub-id-type="doi">10.1021/ci3001919</pub-id>
          <pub-id pub-id-type="pmid">22817270</pub-id>
        </element-citation>
      </ref>
      <ref id="B99-vaccines-11-00263">
        <label>99.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Sun</surname><given-names>J.</given-names></name>
<name><surname>Czerkinsky</surname><given-names>C.</given-names></name>
<name><surname>Holmgren</surname><given-names>J.</given-names></name>
</person-group>
          <article-title>Mucosally Induced Immunological Tolerance, Regulatory T Cells and the Adjuvant Effect by Cholera Toxin B Subunit</article-title>
          <source>Scand. J. Immunol.</source>
          <year>2010</year>
          <volume>71</volume>
          <fpage>1</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-3083.2009.02321.x</pub-id>
          <pub-id pub-id-type="pmid">20017804</pub-id>
        </element-citation>
      </ref>
      <ref id="B100-vaccines-11-00263">
        <label>100.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Sargsyan</surname><given-names>K.</given-names></name>
<name><surname>Grauffel</surname><given-names>C.</given-names></name>
<name><surname>Lim</surname><given-names>C.</given-names></name>
</person-group>
          <article-title>How Molecular Size Impacts RMSD Applications in Molecular Dynamics Simulations</article-title>
          <source>J. Chem. Theory Comput.</source>
          <year>2017</year>
          <volume>13</volume>
          <fpage>1518</fpage>
          <lpage>1524</lpage>
          <pub-id pub-id-type="doi">10.1021/acs.jctc.7b00028</pub-id>
          <pub-id pub-id-type="pmid">28267328</pub-id>
        </element-citation>
      </ref>
      <ref id="B101-vaccines-11-00263">
        <label>101.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Ahmad</surname><given-names>S.</given-names></name>
<name><surname>Raza</surname><given-names>S.</given-names></name>
<name><surname>Uddin</surname><given-names>R.</given-names></name>
<name><surname>Azam</surname><given-names>S.S.</given-names></name>
</person-group>
          <article-title>Binding Mode Analysis, Dynamic Simulation and Binding Free Energy Calculations of the MurF Ligase from Acinetobacter Baumannii</article-title>
          <source>J. Mol. Graph. Model.</source>
          <year>2017</year>
          <volume>77</volume>
          <fpage>72</fpage>
          <lpage>85</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jmgm.2017.07.024</pub-id>
          <pub-id pub-id-type="pmid">28843462</pub-id>
        </element-citation>
      </ref>
      <ref id="B102-vaccines-11-00263">
        <label>102.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Bergstr&#xF6;m</surname><given-names>C.A.S.</given-names></name>
<name><surname>Larsson</surname><given-names>P.</given-names></name>
</person-group>
          <article-title>Computational Prediction of Drug Solubility in Water-Based Systems: Qualitative and Quantitative Approaches Used in the Current Drug Discovery and Development Setting</article-title>
          <source>Int. J. Pharm.</source>
          <year>2018</year>
          <volume>540</volume>
          <fpage>185</fpage>
          <lpage>193</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ijpharm.2018.01.044</pub-id>
          <pub-id pub-id-type="pmid">29421301</pub-id>
        </element-citation>
      </ref>
      <ref id="B103-vaccines-11-00263">
        <label>103.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Ben-Shalom</surname><given-names>I.</given-names></name>
<name><surname>Lin</surname><given-names>C.</given-names></name>
<name><surname>Radak</surname><given-names>B.</given-names></name>
<name><surname>Sherman</surname><given-names>W.</given-names></name>
<name><surname>Gilson</surname><given-names>M.</given-names></name>
</person-group>
          <article-title>Fast Equilibration of Water between Buried Sites and Bulk by MD with Parallel Monte Carlo Water Moves on GPUs</article-title>
          <source>ChemRxiv</source>
          <year>2021</year>
          <comment>Available online: <ext-link xlink:href="https://chemrxiv.org/engage/chemrxiv/article-details/6123cb101d1cc2684fcab40a" ext-link-type="uri">https://chemrxiv.org/engage/chemrxiv/article-details/6123cb101d1cc2684fcab40a</ext-link></comment>
          <date-in-citation content-type="access-date" iso-8601-date="2022-10-16">(accessed on 16 October 2022)</date-in-citation>
        </element-citation>
      </ref>
      <ref id="B104-vaccines-11-00263">
        <label>104.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Tacconelli</surname><given-names>E.</given-names></name>
<name><surname>Carrara</surname><given-names>E.</given-names></name>
<name><surname>Savoldi</surname><given-names>A.</given-names></name>
<name><surname>Harbarth</surname><given-names>S.</given-names></name>
<name><surname>Mendelson</surname><given-names>M.</given-names></name>
<name><surname>Monnet</surname><given-names>D.L.</given-names></name>
<name><surname>Pulcini</surname><given-names>C.</given-names></name>
<name><surname>Kahlmeter</surname><given-names>G.</given-names></name>
<name><surname>Kluytmans</surname><given-names>J.</given-names></name>
<name><surname>Carmeli</surname><given-names>Y.</given-names></name>
<etal/>
</person-group>
          <article-title>Discovery, Research, and Development of New Antibiotics: The WHO Priority List of Antibiotic-Resistant Bacteria and Tuberculosis</article-title>
          <source>Lancet Infect Dis.</source>
          <year>2018</year>
          <volume>18</volume>
          <fpage>318</fpage>
          <lpage>327</lpage>
          <pub-id pub-id-type="doi">10.1016/S1473-3099(17)30753-3</pub-id>
          <pub-id pub-id-type="pmid">29276051</pub-id>
        </element-citation>
      </ref>
      <ref id="B105-vaccines-11-00263">
        <label>105.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Tacconelli</surname><given-names>E.</given-names></name>
<name><surname>Magrini</surname><given-names>N.</given-names></name>
<name><surname>Kahlmeter</surname><given-names>G.</given-names></name>
<name><surname>Singh</surname><given-names>N.</given-names></name>
</person-group>
          <article-title>Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics</article-title>
          <source>World Health Organ.</source>
          <year>2017</year>
          <volume>27</volume>
          <comment>Available online: <ext-link xlink:href="https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30753-3/fulltext" ext-link-type="uri">https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30753-3/fulltext</ext-link></comment>
          <date-in-citation content-type="access-date" iso-8601-date="2022-10-16">(accessed on 16 October 2022)</date-in-citation>
        </element-citation>
      </ref>
      <ref id="B106-vaccines-11-00263">
        <label>106.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Bijker</surname><given-names>M.S.</given-names></name>
<name><surname>Melief</surname><given-names>C.J.M.</given-names></name>
<name><surname>Offringa</surname><given-names>R.</given-names></name>
<name><surname>van der Burg</surname><given-names>S.H.</given-names></name>
</person-group>
          <article-title>Design and Development of Synthetic Peptide Vaccines: Past, Present and Future</article-title>
          <source>Expert Rev. Vaccines</source>
          <year>2007</year>
          <volume>6</volume>
          <fpage>591</fpage>
          <lpage>603</lpage>
          <pub-id pub-id-type="doi">10.1586/14760584.6.4.591</pub-id>
          <pub-id pub-id-type="pmid">17669012</pub-id>
        </element-citation>
      </ref>
      <ref id="B107-vaccines-11-00263">
        <label>107.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>L.</given-names></name>
</person-group>
          <article-title>Multi-Epitope Vaccines: A Promising Strategy against Tumors and Viral Infections</article-title>
          <source>Cell. Mol. Immunol.</source>
          <year>2018</year>
          <volume>15</volume>
          <fpage>182</fpage>
          <pub-id pub-id-type="doi">10.1038/cmi.2017.92</pub-id>
          <pub-id pub-id-type="pmid">28890542</pub-id>
        </element-citation>
      </ref>
      <ref id="B108-vaccines-11-00263">
        <label>108.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Rappuoli</surname><given-names>R.</given-names></name>
</person-group>
          <article-title>From Pasteur to Genomics: Progress and Challenges in Infectious Diseases</article-title>
          <source>Nat. Med.</source>
          <year>2004</year>
          <volume>10</volume>
          <fpage>1177</fpage>
          <pub-id pub-id-type="doi">10.1038/nm1129</pub-id>
          <pub-id pub-id-type="pmid">15516917</pub-id>
        </element-citation>
      </ref>
      <ref id="B109-vaccines-11-00263">
        <label>109.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
<name><surname>del Tordello</surname><given-names>E.</given-names></name>
<name><surname>Rappuoli</surname><given-names>R.</given-names></name>
<name><surname>Delany</surname><given-names>I.</given-names></name>
</person-group>
          <article-title>Reverse Vaccinology: Exploiting Genomes for Vaccine Design</article-title>
          <source>Human Vaccines</source>
          <publisher-name>Elsevier</publisher-name>
          <publisher-loc>Amsterdam, The Netherlands</publisher-loc>
          <year>2017</year>
          <fpage>65</fpage>
          <lpage>86</lpage>
        </element-citation>
      </ref>
      <ref id="B110-vaccines-11-00263">
        <label>110.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Shevtsov</surname><given-names>A.</given-names></name>
<name><surname>Syzdykov</surname><given-names>M.</given-names></name>
<name><surname>Kuznetsov</surname><given-names>A.</given-names></name>
<name><surname>Shustov</surname><given-names>A.</given-names></name>
<name><surname>Shevtsova</surname><given-names>E.</given-names></name>
<name><surname>Berdimuratova</surname><given-names>K.</given-names></name>
<name><surname>Mukanov</surname><given-names>K.</given-names></name>
<name><surname>Ramankulov</surname><given-names>Y.</given-names></name>
</person-group>
          <article-title>Antimicrobial Susceptibility of Brucella Melitensis in Kazakhstan</article-title>
          <source>Antimicrob. Resist Infect. Control.</source>
          <year>2017</year>
          <volume>6</volume>
          <fpage>1</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="doi">10.1186/s13756-017-0293-x</pub-id>
          <pub-id pub-id-type="pmid">29299304</pub-id>
        </element-citation>
      </ref>
      <ref id="B111-vaccines-11-00263">
        <label>111.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Ehsan</surname><given-names>N.</given-names></name>
<name><surname>Ahmad</surname><given-names>S.</given-names></name>
<name><surname>Navid</surname><given-names>A.</given-names></name>
<name><surname>Azam</surname><given-names>S.S.</given-names></name>
</person-group>
          <article-title>Identification of Potential Antibiotic Targets in the Proteome of Multi-Drug Resistant Proteus Mirabilis</article-title>
          <source>Meta Gene</source>
          <year>2018</year>
          <volume>18</volume>
          <fpage>167</fpage>
          <lpage>173</lpage>
          <pub-id pub-id-type="doi">10.1016/j.mgene.2018.09.004</pub-id>
        </element-citation>
      </ref>
      <ref id="B112-vaccines-11-00263">
        <label>112.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Gul</surname><given-names>S.</given-names></name>
<name><surname>Ahmad</surname><given-names>S.</given-names></name>
<name><surname>Ullah</surname><given-names>A.</given-names></name>
<name><surname>Ismail</surname><given-names>S.</given-names></name>
<name><surname>Khurram</surname><given-names>M.</given-names></name>
<name><surname>Tahir ul Qamar</surname><given-names>M.</given-names></name>
<name><surname>Hakami</surname><given-names>A.R.</given-names></name>
<name><surname>Alkhathami</surname><given-names>A.G.</given-names></name>
<name><surname>Alrumaihi</surname><given-names>F.</given-names></name>
<name><surname>Allemailem</surname><given-names>K.S.</given-names></name>
</person-group>
          <article-title>Designing a Recombinant Vaccine against Providencia Rettgeri Using Immunoinformatics Approach</article-title>
          <source>Vaccines</source>
          <year>2022</year>
          <volume>10</volume>
          <elocation-id>189</elocation-id>
          <pub-id pub-id-type="doi">10.3390/vaccines10020189</pub-id>
          <pub-id pub-id-type="pmid">35214648</pub-id>
        </element-citation>
      </ref>
      <ref id="B113-vaccines-11-00263">
        <label>113.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Munia</surname><given-names>M.</given-names></name>
<name><surname>Mahmud</surname><given-names>S.</given-names></name>
<name><surname>Mohasin</surname><given-names>M.</given-names></name>
<name><surname>Kibria</surname><given-names>K.M.K.</given-names></name>
</person-group>
          <article-title>In Silico Design of an Epitope-Based Vaccine against Choline Binding Protein A of Streptococcus Pneumoniae</article-title>
          <source>Inf. Med. Unlocked</source>
          <year>2021</year>
          <volume>23</volume>
          <fpage>100546</fpage>
          <pub-id pub-id-type="doi">10.1016/j.imu.2021.100546</pub-id>
        </element-citation>
      </ref>
      <ref id="B114-vaccines-11-00263">
        <label>114.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Zargaran</surname><given-names>F.N.</given-names></name>
<name><surname>Akya</surname><given-names>A.</given-names></name>
<name><surname>Rezaeian</surname><given-names>S.</given-names></name>
<name><surname>Ghadiri</surname><given-names>K.</given-names></name>
<name><surname>Lorestani</surname><given-names>R.C.</given-names></name>
<name><surname>Madanchi</surname><given-names>H.</given-names></name>
<name><surname>Safaei</surname><given-names>S.</given-names></name>
<name><surname>Rostamian</surname><given-names>M.</given-names></name>
</person-group>
          <article-title>B Cell Epitopes of Four Fimbriae Antigens of Klebsiella Pneumoniae: A Comprehensive in Silico Study for Vaccine Development</article-title>
          <source>Int. J. Pept. Res. Ther.</source>
          <year>2021</year>
          <volume>27</volume>
          <fpage>875</fpage>
          <lpage>886</lpage>
          <pub-id pub-id-type="doi">10.1007/s10989-020-10134-3</pub-id>
          <pub-id pub-id-type="pmid">33250677</pub-id>
        </element-citation>
      </ref>
      <ref id="B115-vaccines-11-00263">
        <label>115.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Li</surname><given-names>M.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
<name><surname>Niu</surname><given-names>C.</given-names></name>
<name><surname>Xie</surname><given-names>X.</given-names></name>
<name><surname>Haimiti</surname><given-names>G.</given-names></name>
<name><surname>Guo</surname><given-names>W.</given-names></name>
<name><surname>Yu</surname><given-names>M.</given-names></name>
<name><surname>Chen</surname><given-names>Z.</given-names></name>
<name><surname>Ding</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>F.</given-names></name>
</person-group>
          <article-title>Design of a Multi-Epitope Vaccine Candidate against Brucella Melitensis</article-title>
          <source>Sci. Rep.</source>
          <year>2022</year>
          <volume>12</volume>
          <elocation-id>10146</elocation-id>
          <pub-id pub-id-type="doi">10.1038/s41598-022-14427-z</pub-id>
          <pub-id pub-id-type="pmid">35710873</pub-id>
        </element-citation>
      </ref>
      <ref id="B116-vaccines-11-00263">
        <label>116.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Yao</surname><given-names>M.</given-names></name>
<name><surname>Guo</surname><given-names>X.</given-names></name>
<name><surname>Wu</surname><given-names>X.</given-names></name>
<name><surname>Bai</surname><given-names>Q.</given-names></name>
<name><surname>Sun</surname><given-names>M.</given-names></name>
<name><surname>Yin</surname><given-names>D.</given-names></name>
</person-group>
          <article-title>Evaluation of the Combined Use of Major Outer Membrane Proteins in the Serodiagnosis of Brucellosis</article-title>
          <source>Infect. Drug Resist.</source>
          <year>2022</year>
          <volume>15</volume>
          <fpage>4093</fpage>
          <lpage>4100</lpage>
          <pub-id pub-id-type="doi">10.2147/IDR.S372411</pub-id>
          <pub-id pub-id-type="pmid">35924021</pub-id>
        </element-citation>
      </ref>
      <ref id="B117-vaccines-11-00263">
        <label>117.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Kazi</surname><given-names>A.</given-names></name>
<name><surname>Chuah</surname><given-names>C.</given-names></name>
<name><surname>Majeed</surname><given-names>A.B.A.</given-names></name>
<name><surname>Leow</surname><given-names>C.H.</given-names></name>
<name><surname>Lim</surname><given-names>B.H.</given-names></name>
<name><surname>Leow</surname><given-names>C.Y.</given-names></name>
</person-group>
          <article-title>Current Progress of Immunoinformatics Approach Harnessed for Cellular-and Antibody-Dependent Vaccine Design</article-title>
          <source>Pathog Glob Health</source>
          <year>2018</year>
          <volume>112</volume>
          <fpage>123</fpage>
          <lpage>131</lpage>
          <pub-id pub-id-type="doi">10.1080/20477724.2018.1446773</pub-id>
          <pub-id pub-id-type="pmid">29528265</pub-id>
        </element-citation>
      </ref>
      <ref id="B118-vaccines-11-00263">
        <label>118.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>N.</given-names></name>
<name><surname>Khan</surname><given-names>F.</given-names></name>
<name><surname>Kumar</surname><given-names>A.</given-names></name>
</person-group>
          <article-title>Exploring Highly Antigenic Protein of Campylobacter Jejuni for Designing Epitope Based Vaccine: Immunoinformatics Approach</article-title>
          <source>Int. J. Pept. Res. Ther.</source>
          <year>2019</year>
          <volume>25</volume>
          <fpage>1159</fpage>
          <lpage>1172</lpage>
          <pub-id pub-id-type="doi">10.1007/s10989-018-9764-z</pub-id>
        </element-citation>
      </ref>
      <ref id="B119-vaccines-11-00263">
        <label>119.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
<name><surname>Sheth</surname><given-names>H.B.</given-names></name>
<name><surname>Glasier</surname><given-names>L.M.</given-names></name>
<name><surname>Ellert</surname><given-names>N.W.</given-names></name>
<name><surname>Cachia</surname><given-names>P.</given-names></name>
<name><surname>Kohn</surname><given-names>W.</given-names></name>
<name><surname>Lee</surname><given-names>K.K.</given-names></name>
<name><surname>Paranchych</surname><given-names>W.</given-names></name>
<name><surname>Hodges</surname><given-names>R.S.</given-names></name>
<name><surname>Irvin</surname><given-names>R.T.</given-names></name>
</person-group>
          <article-title>Development of an Anti-Adhesive Vaccine for Pseudomonas Aeruginosa Targeting the C-Terminal Region of the Pilin Structural Protein</article-title>
          <source>Biomed Pept. Proteins Nucleic Acids</source>
          <year>1995</year>
          <volume>1</volume>
          <fpage>141</fpage>
          <lpage>148</lpage>
          <pub-id pub-id-type="pmid">9346845</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig position="float" id="vaccines-11-00263-f001">
      <label>Figure 1</label>
      <caption>
        <p>Outline of methodology that was used for designing a multi-epitopes vaccine against <italic toggle="yes">B. melitensis</italic>.</p>
      </caption>
      <graphic xlink:href="vaccines-11-00263-g001" position="float"/>
    </fig>
    <fig position="float" id="vaccines-11-00263-f002">
      <label>Figure 2</label>
      <caption>
        <p>Shortlisted proteins in each step of subtractive proteomics filter.</p>
      </caption>
      <graphic xlink:href="vaccines-11-00263-g002" position="float"/>
    </fig>
    <fig position="float" id="vaccines-11-00263-f003">
      <label>Figure 3</label>
      <caption>
        <p>Pan-core plot. The number of fully sequenced proteomes used are plotted on the X-axis while gene families are plotted against each proteome on the Y-axis.</p>
      </caption>
      <graphic xlink:href="vaccines-11-00263-g003" position="float"/>
    </fig>
    <fig position="float" id="vaccines-11-00263-f004">
      <label>Figure 4</label>
      <caption>
        <p>Schematic representation of multi-epitopes vaccine.</p>
      </caption>
      <graphic xlink:href="vaccines-11-00263-g004" position="float"/>
    </fig>
    <fig position="float" id="vaccines-11-00263-f005">
      <label>Figure 5</label>
      <caption>
        <p>Three-dimensional structure of designed vaccine.</p>
      </caption>
      <graphic xlink:href="vaccines-11-00263-g005" position="float"/>
    </fig>
    <fig position="float" id="vaccines-11-00263-f006">
      <label>Figure 6</label>
      <caption>
        <p>Left side picture represents wild type structure while right side picture represents mutated structure.</p>
      </caption>
      <graphic xlink:href="vaccines-11-00263-g006" position="float"/>
    </fig>
    <fig position="float" id="vaccines-11-00263-f007">
      <label>Figure 7</label>
      <caption>
        <p>Cloning of multi-epitopes vaccine constructs (yellow color) into pET28a (+) vector.</p>
      </caption>
      <graphic xlink:href="vaccines-11-00263-g007" position="float"/>
    </fig>
    <fig position="float" id="vaccines-11-00263-f008">
      <label>Figure 8</label>
      <caption>
        <p>Intermolecular docked conformation of complexes. (<bold>A</bold>) vaccine-MHC-I complex, (<bold>B</bold>) vaccine-MHC-II complex and (<bold>C</bold>) vaccine-TLR-4 complex.</p>
      </caption>
      <graphic xlink:href="vaccines-11-00263-g008" position="float"/>
    </fig>
    <fig position="float" id="vaccines-11-00263-f009">
      <label>Figure 9</label>
      <caption>
        <p>Simulation trajectories (<bold>A</bold>) RMSD (<bold>B</bold>) RMSF.</p>
      </caption>
      <graphic xlink:href="vaccines-11-00263-g009" position="float"/>
    </fig>
    <table-wrap position="float" id="vaccines-11-00263-t001">
      <object-id pub-id-type="pii">vaccines-11-00263-t001_Table 1</object-id>
      <label>Table 1</label>
      <caption>
        <p>Predicted B-cells epitopes. The epitopes vary in length and have higher scores than the threshold.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Proteins</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Predicted B-Cells Epitopes</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">core/352/1/Org1_Gene809 (catalase)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GAPIPDNQNSLTAGERGPILMQ</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KRHPRTHLRSAT</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">QGHKHWTNAEAEQVIGRTREST</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HRLGTHYESIPVNQPKCPVHHYH</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GIKTGNPDAYYEPNSFNGPVEQPSAKEPPLCISG</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ADRYNHRIGNDDYS</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LKDAHGYDANTIALNEKI</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KRHPRTHLRSAT</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">QGHKHWTNAEAEQVIGRTREST</td>
          </tr>
          <tr>
            <td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">core/1230/1/Org1_Gene1297 (siderophore ABC transporter substrate-binding protein)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VPFPEYLKKYQGDDYAKVGTLFEPDYEAVNA</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EAEAKAEAEKLNKELAA</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PAAPNLSIGNHGQPISSE</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DAAIGREGNSAKQ</td>
          </tr>
          <tr>
            <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">core/2014/1/Org1_Gene1274 (pyridoxamine 5&#x2032;-phosphate oxidase)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SSDDFTQSAEPF</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DAEADAYYASRPR</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">QSRPLESRFALE</td>
          </tr>
          <tr>
            <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">core/2047/1/Org1_Gene1622 (superoxide dismutase)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LPALPYDYDALAPFMSRE</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GLEGKSLEEIVK</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">core/2062/1/Org1_Gene1723 (peptidylprolyl isomerase)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VKFGNMDKGFDAARVGTGGSNYPDLPAEFSKEPF</td>
          </tr>
          <tr>
            <td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">core/2194/1/Org1_Gene1299 (superoxide dismutase family protein)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SCAPGEKDGKIVPA</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HYDPGNTHHHLGPEGDGHMG</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GDNYSDKPEPLGGGG</td>
          </tr>
          <tr>
            <td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">core/123/4/Org4_Gene2756 (septation protein A)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DGSKKTPEQLDRERRLAQAMID</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LAGNIKQARADNAEKAGIEGAAKKFAGLDLGSLLSGGAAYPSAVAGGASPTSGAATGTTPTTGATVDLSGDKQKF</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VINGQRVKINDSFRTFASP</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">INLPQQAQPQGVQVASLDPSIGMAQAYAPEPQPQTAAAAINQIAPQQPVPEAKISDALLRQNDMALGGALAPQGQAPQQVADTSGYFPAAPSADSAPIMGSYAAPRQGGVN</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DALRAKPQTEYGFTTLPDGTVLRTDKRSGNAEPIYSAGQKPTSDMQEY</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FAVSQGFKGSFADYQQAMKKAGASSTNVSVGEGDKFYEALDKKNAD</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DAGIQARSKLAQIERLGGLMQASPT</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LVPQQRQPGSGPMSDA</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">QYQIQMGDIADQVANREISAAEGRNRIKNLKNPLEGFRTSTKDKTPGKSGVSGNRLRFNPQTG</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">core/389/1/Org1_Gene1317 (hypothetical protein)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SVVSRNISGAKDADYSRR</td>
          </tr>
          <tr>
            <td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SALYSADNYSGSPSG</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VVGGTRMGRDVSDYLDQRDAL</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ARKVTFEQSAVLTPGVAGKAVTVDGVPLSHDTFDQPFGTG</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ESDQTGSSPDQTGLFSWSGSPAIPGAGLSAGIAGTIEVSVPFIASEGGSALLLRDGGANGANYKYNVQGAAGFSDRLRALNEAFSEPMVFDAAAGISSSSSLIGYS</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KRQKANSEFTYNGT</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FALSNATGVDID</td>
          </tr>
          <tr>
            <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">core/2225/1/Org1_Gene971 (Binding-protein-dependent transport systems inner membrane component)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SKKNLPNNAGDLGLGAGAATPGSSQ</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ISYGNERPVAVCDADTCWSQ</td>
          </tr>
          <tr>
            <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">core/2432/1/Org1_Gene927 (4-hydroxy-2-oxoheptanedioate aldolase)</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SPVGSNTTNSASTASNSTSAANKASVDYD</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NQDPTQPMDPTQY</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap position="float" id="vaccines-11-00263-t002">
      <object-id pub-id-type="pii">vaccines-11-00263-t002_Table 2</object-id>
      <label>Table 2</label>
      <caption>
        <p>Selected epitopes for vaccine construct.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Selected Epitopes</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antigenicity</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Allergen City</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Water Solubility</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Toxicity</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WTNAEAEQV</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.637</td>
            <td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Non-Allergenic</td>
            <td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Good water soluble</td>
            <td rowspan="9" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Non-toxigenic</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EAEAKAEAE</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.62</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EADAYYASR</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.93</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GLEGKSLEE</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.9</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KGFDAARVG</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.7</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">YAPEPQPQT</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.8</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">REISAAEGR</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.7</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KSGVSGNRL</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9526</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ESDQTGSSP</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.0515</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap position="float" id="vaccines-11-00263-t003">
      <object-id pub-id-type="pii">vaccines-11-00263-t003_Table 3</object-id>
      <label>Table 3</label>
      <caption>
        <p>Pairs of amino-acid residues Chi-3 values and energy.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Amino Acid Residues Pairs</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Chi3</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Energy</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ser 15-Pro23</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72.16</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.8</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tyr 18-Thr22</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;69.94</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.3</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">His 20-Ala59</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">124.08</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.12</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gln 24-Glu57</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">112.52</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.75</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ile 38-Leu41</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">110.17</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.3</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thr 49-Ala53</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">102.94</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.53</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phe 69-His78</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;73.43</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.77</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gln 70-Val73</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">105.4</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.08</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ala 101-Ala123</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">124.39</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.67</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cys 107-Lys112</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">112.51</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.94</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gly 135-Asn142</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">102.4</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.24</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Asn 161-Ala183</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">110.79</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.33</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lys 196-Ser201</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">110.02</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.36</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pro 222-Gln229</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">109.88</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.95</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pro 250-Ser253</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87.28</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.32</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ser 253-Gly257</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.61</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.49</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gly 265-Ser272</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;101.99</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.73</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap position="float" id="vaccines-11-00263-t004">
      <object-id pub-id-type="pii">vaccines-11-00263-t004_Table 4</object-id>
      <label>Table 4</label>
      <caption>
        <p>Model, RMSD, MolProbity, clash score, poor rotamers, Rama-favored and GALAXY energy of refined complexes.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Model</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">RMSD</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MolProbity</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clash Score</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Poor Rotamers</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Rama <break/>Favored</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Galaxy Energy</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Initial</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.000</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.643</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92.4</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.0</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87.1</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27,990.35</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Model 1</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.948</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.475</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.3</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92.6</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;4210.72</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Model 2</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.892</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.396</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.9</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93.0</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;4210.18</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Model 3</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.434</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.475</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.3</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92.6</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;4201.35</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Model 4</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.942</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.503</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.3</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91.9</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;4198.98</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Model 5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.841</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.445</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.3</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93.4</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;4197.66</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Model 6</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.815</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.314</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.6</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94.1</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;4196.15</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Model 7</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.469</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.258</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92.3</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;4195.66</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Model 8</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.952</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.202</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.7</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92.3</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;4191.22</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Model 9</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.849</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.349</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.4</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92.3</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;4189.56</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Model 10</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.932</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.475</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.3</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92.6</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;4189.56</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap position="float" id="vaccines-11-00263-t005">
      <object-id pub-id-type="pii">vaccines-11-00263-t005_Table 5</object-id>
      <label>Table 5</label>
      <caption>
        <p>Top 10 refined complexes of vaccine and MHC-I molecule. vdW (van der Waals energy), ACE (atomic contact energy), and HB (hydrogen bond energy).</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Rank</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Solution <break/>Number</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Global Energy</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Attractive VdW</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Repulsive VdW</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">ACE</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HB</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;5.48</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;5.02</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.19</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.69</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.79</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;25.90</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.18</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.87</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;2.19</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.98</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;4.25</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.70</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;2.11</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.47</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;2.11</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.28</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.13</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;1.94</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;0.09</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23.01</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;42.36</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.05</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.51</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;4.03</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67.55</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;64.86</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">217.80</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.60</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;8.81</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68.38</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;38.43</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">155.88</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.27</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;7.66</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">107.39</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;50.90</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">220.11</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.40</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;8.98</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4497.19</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;69.73</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5774.65</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;4.08</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;10.33</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap position="float" id="vaccines-11-00263-t006">
      <object-id pub-id-type="pii">vaccines-11-00263-t006_Table 6</object-id>
      <label>Table 6</label>
      <caption>
        <p>Top 10 refined complexes of vaccine and MHC-II molecule. vdW (van der Waals energy), ACE (atomic contact energy), and HB (hydrogen bond energy).</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Rank</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Solution Number</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Global Energy</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Attractive VdW</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Repulsive VdW</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">ACE</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HB</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.64</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;3.25</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.36</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;0.27</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.11</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;0.46</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.30</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.66</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;0.00</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.49</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;5.54</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.04</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.39</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25.99</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;4.47</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.30</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;0.38</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36.43</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;4.81</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.30</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.13</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68.21</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;33.20</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">129.09</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.91</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;2.55</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1005.87</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;47.94</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1306.99</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.39</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;5.44</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1285.73</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;45.58</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1683.22</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;6.34</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;3.73</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1663.10</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;38.48</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2141.13</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.25</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;2.73</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap position="float" id="vaccines-11-00263-t007">
      <object-id pub-id-type="pii">vaccines-11-00263-t007_Table 7</object-id>
      <label>Table 7</label>
      <caption>
        <p>Top 10 refined complexes of vaccine and TLR-4 molecule. vdW (van der Waals energy), ACE (atomic contact energy), and HB (hydrogen bond energy).</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Rank</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Solution Number</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Global Energy</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Attractive VdW</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Repulsive VdW</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">ACE</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HB</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;2.69</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;2.65</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.51</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.53</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;25.46</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.39</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.38</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;1.62</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.05</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;6.07</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.39</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;1.62</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;0.33</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.64</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;39.02</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35.23</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.74</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;7.23</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24.74</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;12.29</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.51</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.35</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;1.00</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34.77</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;18.81</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.52</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.81</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;0.76</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">113.53</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;41.79</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">199.10</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.01</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;5.16</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">355.02</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;21.74</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">471.02</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;3.09</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;1.73</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">452.38</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;29.95</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">571.85</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.56</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;4.40</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4146.04</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;63.37</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5273.51</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.33</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;11.76</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap position="float" id="vaccines-11-00263-t008">
      <object-id pub-id-type="pii">vaccines-11-00263-t008_Table 8</object-id>
      <label>Table 8</label>
      <caption>
        <p>Binding free energies calculation. The units are kcal/mol.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Energy Parameter</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TLR-4-Vaccine Complex</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MHC-I-Vaccine Complex</th>
            <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MHC-II-Vaccine Complex</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">MM-GBSA</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VDWAALS</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;150.96</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;137.99</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;131.57</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EEL</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;96.37</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;81.61</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;80.22</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EGB</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35.00</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32.08</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.00</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ESURF</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;22.85</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;19.27</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;21.94</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Delta G gas</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;247.33</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;219.6</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;211.79</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Delta G solv</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.15</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.81</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;3.94</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Delta Total</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;259.48</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;206.79</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;215.73</td>
          </tr>
          <tr>
            <td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">MM-PBSA</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VDWAALS</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;150.96</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;137.99</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;131.57</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EEL</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;96.37</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;81.61</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;80.22</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EPB</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35.00</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32.08</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.00</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ENPOLAR</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;22.85</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;19.27</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;21.94</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Delta G gas</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;247.33</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;219.6</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;211.79</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Delta G solv</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.15</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.81</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;3.94</td>
          </tr>
          <tr>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Delta Total</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;235.18</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;206.79</td>
            <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x2212;215.73</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
  </floats-group>
</article>
</pmc-articleset>